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IMMORTALIZATION 
AND MALIGNANT TRANSFORMATION 
OF EUKARYOTIC CELLS
The process of cellular transformation has been amply 
studied in vitro using immortalized cell lines. Immortal-
ized cells never have the normal diploid karyotype, nev-
ertheless, they cannot grow over one another in cell cul-
ture (contact inhibition), do not form colonies in soft agar 
(anchorage-dependent growth) and do not form tumors 
when injected into immunodeficient rodents. All these 
characteristics can be obtained with additional chromo-
some changes. Multiple genetic rearrangements, includ-
ing whole chromosome and gene copy number gains and 
losses, chromosome translocations, gene mutations are 
necessary for establishing the malignant cell phenotype. 
Most of the experiments detecting transforming ability of 
genes overexpressed and/or mutated in tumors (onco-
genes) were performed using mouse embryonic fibroblasts 
(MEFs), NIH3T3 mouse fibroblast cell line, human 
embryonic kidney 293 cell line (HEK293), and human 
mammary epithelial cell lines (mainly HMECs and MC-
F10A). These cell lines have abnormal karyotypes and 
are prone to progress to malignantly transformed cells. 
This review is aimed at understanding the mechanisms of 
cell immortalization by different «immortalizing agents», 
oncogene-induced cell transformation of immortalized 
cells and moderate response of the advanced tumors to 
anticancer therapy in the light of tumor «oncogene and 
chromosome addiction», intra-/intertumor heterogeneity, 
and chromosome instability.  
Introduction. Malignant transformation is the 
process by which cells acquire the properties of 
cancer. The first successful malignant transfor-
mation in vitro was achieved with the polyoma 
virus on Syrian hamster embryo cells, followed 
by transformation with chemical carcinogens in 
the mid-1960th (reviewed in [1]). Reports of hu-
man cell transformation using viruses and viral 
oncogenes appeared only in the late 1970th [1]. In 
early 80th it was shown that immortalized NIH3T3 
mouse fibroblast cells introduced with total ge-
nomic DNA from human tumors were converted 
into cancer cells; later it was found that H-RAS 
gene harboring a point mutation induced trans-
formation of NIH3T3 cells in culture and con-
ferred on them the ability to induce tumors in 
nude mice (reviewed in [2]). These discoveries 
marked an advent of the intense searching for the 
abnormal genes influencing the development of 
human cancer that continues today [3]. 
Early works stated that in vitro transformation 
of human cells by a single carcinogenic agent in 
contrast to rodent cells was an extraordinarily 
rare event [1]. Moreover, a spontaneous im-
mortalization following senescence was also an 
extremely rare event in human fibroblasts and 
epithelial cells, although it occurred commonly 
in rodent cells with varying frequencies depend-
ing on species from which the cells were derived 
[1, 4]. One of the explanations of intrinsic anti-
neoplastic mechanisms of human cells was dif-
ferences in telomere biology between human and 
murine cells. Mouse cells begin their replication 
ex vivo with extremely long telomeres: 3–10-fold 
longer than in identical human cells and the ten-
dency for progressive telomere erosion might ef-
fectively be countered by the basal telomerase ac-
tivity that is constitutively present in mouse cells 
[1, 4–8]. Additionally, the basal metabolic rate is 
about 7-fold higher in mice than in humans and 
this affects the levels of endogenous oxidants and 
other mutagens that are produced as by-products 
of normal oxidative metabolism resulting in 18-
fold more breakdown products of DNA in mice 
[4]. Moreover, the rates of metabolic conversion 
of procarcinogens to carcinogens and the detoxi-
fication of many other potential mutagens can 
occur with greatly differing kinetics [4]. Further-
more, humans have more efficient DNA repair 
system, and the rate of 5-methylcytosine decline 
during cellular senescence is much slower in hu-
man cells than in mouse cells [1].
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Nevertheless, telomerase-deficient primary 
mouse embryonic fibroblasts (MEFs) could be 
immortalized/transformed in culture, and gener-
ated tumors in nude mice following transforma-
tion [9]. It was concluded that telomerase is not 
required for establishment of immortalized cell 
lines, oncogenic transformation, or tumor forma-
tion in mice. Another research group transformed 
human primary fibroblasts and human primary 
mesodermal cells introducing simultaneously three
oncogenes E1A, MDM2, and H-RASV12. These 
cells formed colonies in soft agar and tumors in 
mice, but they and the majority of the tumors 
derived from them lacked telomerase activity, 
and telomere erosion was observed [10]. Authors 
have deduced that telomere maintenance is not 
obligatory for tumorigenic conversion. To the 
point, human primary melanomas show telomere 
maintenance as a late event in tumor progression 
(metastatic melanoma), thus, telomere mainte-
nance/immortalization is associated with pro-
gression rather than initiation of melanoma [11]. 
Furthermore, like primary human cells, pri-
mary MEFs require combination of two «hits» 
to acquire the capacity to form tumors [9, 12-
19]. There are also cases of a conversion of nor-
mal primary rodent [20–23] and human [24–27] 
cells to fully transformed cells with a single on-
cogene under specific experimental (significant 
overexpression of oncogene) and culture con-
ditions. Culture conditions significantly affect 
proliferative (before senescence) [5] and trans-
formation potential of cells [8]. For example, 
wild type MEFs grown in serum-free medium 
supplemented with defined growth components 
(EGF, PDGF, insulin, high density lipoprotein, 
fibronectin, and transferrin) were refractory to 
transformation by oncogenic RAS + E1A [7]. 
Moreover, RAS + E1A-induced chromosome in-
stability, colony formation and tumorigenesis of 
the p53 –/– serum free-MEFs also could be at-
tenuated by treating the cells with the free-radical 
scavenger N-acetylcysteine [7]. 
Finally, humans live, on average, 30–50 times 
longer than mice and undergo about 105 more 
cell divisions in a lifetime (1016 versus 1011 mi-
toses) [4]. Nevertheless, epidemiological studies 
have revealed that the life-time risk of develop-
ing cancer is comparable in both species. About 
30 % of laboratory rodents have cancer by the 
end of their 2–3 year life-span and about 30 % 
of people have cancer by the end of their 70–80 
year life-span [4]. 
Thus, it seems that in vitro (and likely in vivo) 
transformation process may be fundamentally 
similar in rodent and human cells and be sig-
nificantly affected by non-physiological culture 
conditions in vitro. 
Senescence. In contrast to germ cells and cer-
tain stem cells somatic cells have a limited lifes-
pan, gradually slow in growth, and stop dividing, a 
process known as replicative senescence [28]. The 
finite replicative life span of normal cells in culture 
was first described approximately 50 years ago by 
Leonard Hayflick [29], and is often termed as the 
«Hayflick limit» [30]. The precise number of rep-
licative doublings exhibited by cultured cells before 
they reach senescence depends on the species from 
which the cells are derived, the tissue of origin, 
and the age of the donor organism [31]. Cultured 
human primary fibroblastic cells generally display 
50 to 80 population doublings (PD) [7, 32, 33], 
whereas explanted MEFs can divide just for 15–30 
PD before undergoing senescence [5, 7]. Primary 
normal human astrocytes perform only about 20 
PD before reaching senescence [34]. Human ke-
ratinocytes have an in vitro life span of 15–20 PD 
in serum-free chemically defined media, whereas 
keratinocytes grown on feeder fibroblasts proliferate 
for up to 50 PD [7, 32] and in F medium on feeder 
fibroblasts for up to 80 PD before senescencing 
[35]. Most published reports on cultured human 
epithelial cells have shown active growth for only 
10 to 30 PD [32]. Significantly, simple changes in 
the culture conditions (defined growth factors in-
stead of serum) could permit active growth of hu-
man mammary epithelial cells for up to 60 PD, 
whereas addition of oxytocin (endogenous antioxi-
dant) gave about 20 PD of increased proliferation 
[32]. MEFs proliferate for more than 60 PD with 
no signs of replicative senescence under physiologi-
cal oxygen levels (3 % versus 21 %) [7, 8]. Thus, 
primary cells undergo stress-associated senescence 
due to in vitro non-physiological standard cultur-
ing conditions, including disruption of cell-cell 
contacts, lack of heterotypic interactions between 
different cell types, the medium-to-cell ratio, per-
sistent signaling pathways activation by mitogens, 
absence of appropriate survival factors, hyperoxia, 
and plating on plastic [5]. 
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The process of senescence occurs both in 
vitro and in vivo. Cellular senescence in vivo is 
now recognized to play an active role as a tu-
mor suppressor pathway [36, 37], in the loss of 
regenerative potential in aging tissues and in the 
pathogenesis of cardiovascular diseases [38]. Se-
nescence in vitro is marked by the appearance of 
large, flattened vacuolated cells and character-
ized by the inability of cells to proliferate despite 
the presence of a steady supply of abundant nu-
trients, mitogens [39], ample room for expansion 
[33], and by the maintenance of cell viability/
resistance to apoptosis and metabolic activity for 
months [37, 38, 40]. Once senescence is triggered, 
cells are not capable of re-entering the cell cycle 
or developing into tumors [36]. Moreover, senes-
cent cells secrete a plethora of factors primarily 
involved in insulin-like growth factor and trans-
forming growth factor ȕ signaling, extracellular 
matrix remodeling, and inflammation. Altogether 
these secreted factors were referred to as the «Se-
nescence-Messaging Secretome» or the «Senes-
cence-Associated Secretory Phenotype» [33].
Senescent cells can be distinguished from pre-
senescent, immortal, quiescent or terminally dif-
ferentiated cells by histochemical detection of the 
biomarker senescence-associated ȕ-galactosidase 
[41]. Senescence accompanies changes in nuclear 
morphology and formation of a distinct chro-
matin structure, called senescence-associated 
heterochromatic foci (SAHF). These foci are 
characterized by the accumulation of histone H3 
trimethylated at lysine 9 and recruit heterochro-
matin proteins to the genes that are to be stably 
repressed during senescence [41]. Importantly, 
formation of SAHF and silencing of genes re-
quire an intact pRB pathway, since inhibition of 
p16INK4A prevents SAHF formation and leads to 
DNA replication [33, 41].
The onset of senescence is partly attributable 
to the shortening of telomeres by approximately 
50–200 base pairs with each cell division to a 
threshold where it is recognized as DNA dam-
age and thus initiates replicative senescence [31, 
33, 38]. Critical telomere shortening and even-
tual dysfunction triggers a classical DNA dam-
age response involving a number of cellular pro-
teins, including ataxia telangiectasia mutated 
protein (ATM), check point kinase 1/2 (CHK1 
and CHK2), p16INK4A, p53, 53 binding protein 1 
(53BP1), p21CIP1, nijmegan breakage syndrome 
1 protein (NBS1), plasminogen activator protein 
1 (PAI1), and phosphorylated histone J-H2A.X 
[41]. These cellular factors cooperate to initiate 
senescence, thereby preventing cellular prolifera-
tion in the presence of damaged chromosomes 
and hence limiting the acquisition of potential 
pathogenic mutations [33, 41]. 
However, telomere attrition is not the only 
stimulus for replicative senescence. Oxidative 
stress can induce or accelerate the onset, a phe-
nomenon referred to as stress-induced replicative 
senescence. It occurs in several ways (reviewed 
in [38]): oxidative stress can activate critical cell 
cycle tumor suppressor proteins p53 and pRB by 
oxidative-stress-induced DNA damage such as 
double strand breaks. Oxidative stress can result 
in oxidative modifications of triple guanine re-
peats (TTAGGG) in sequences of telomeric ends 
making them more susceptible to breaks and en-
hancing the rate of telomere attrition. Oxidative-
stress-induced premature senescence might be 
a function of a direct suppression of telomerase 
activity. hTERT gene (encodes catalytic subunit 
of human telomerase) expression is regulated by 
many transcription factors, including AP1, SP1 
and NF-țB, all of which are redox regulated 
[42]. In any case, oxidative stress results in the 
loss of chromosomal integrity as manifested by 
chromosomal fusions, recombination and deg-
radation, and contributes to DNA damage re-
sponses that eventually lead to the irreversible 
cell-cycle arrest/senescence or cell death through 
the activation of p53- and pRB-dependent func-
tions [24, 43]. 
Immortalization. Senescence (telomere erosion-
induced, oncogene-induced [33], or stress-in-
duced [44]) forms a barrier against tumorigen-
esis. Overcoming of senescence and acquisition 
of immortality is an essential step in the pro-
cess of malignant transformation [33, 45]. Cel-
lular immortalization allows a cell to indefi-
nitely proliferate while accumulating genetic 
abnormalities [27, 46]. Immortalized cells can-
not grow over one another (contact inhibition) 
[47, 48], their proliferation ability is growth fac-
tor dependent [49] and their growth is anchor-
age-dependent (cells do not form colonies in 
soft agar) [50–52]. There are several mutually 
complementary mechanisms that contribute to 
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a cell being able to escape senescence and be-
come immortal, including telomere length sta-
bilization, epigenetic gene silencing by selective 
promoter methylation, oxidative DNA damage, 
inactivation of cell cycle regulatory genes such as 
p16INK4A, p53, pRB, p21CIP1, overexpression of a 
cellular oncogenic proteins such as c-MYC, BMI1 
or through expression of viral oncogenes [41]. 
In vitro immortalization of various cell types 
was successfully performed by the introduction of 
viral genomes/oncogenes (Table 1), telomerase 
catalytic subunit (hTERT) (Table 2) as well as by 
enforced expression of transcription factors (e.g. 
c-MYC, BMI1, ZNF217, or ȕ-catenin).
Genomes of viruses encode a number of regu-
latory and structural proteins but «immortalizating 
effect» can be attributed only to several of them. 
For SV40 viral oncoproteins responsible for im-
mortalization correspond to the portion of the 
viral chromosome expressed early after infection, 
which encodes two proteins, the large T-antigen 
and the small t-antigen [92, 93]. For the adenovi-
ruses viral oncoproteins are encoded by a subset of 
the early genes and termed the E1A proteins and 
the E1B proteins [93]. Experiments with the hu-
man papilloma viruses uncovered a similar set of 
early proteins called the E6 and E7 proteins [93, 
94]. In the cell these oncoproteins bind to pRB 
and p53 causing their ubiquitin-dependent pro-
teasomal degradation. It allows going through the 
cell cycle checkpoints in an uncontrolled manner. 
Role of pRB and p53 signaling pathways in cell 
cycle regulation is presented in Figure. Cells ex-
pressing these viral oncogenes continue proliferat-
ing beyond the population doubling level, at which 
their untreated counterparts become senescent, 
but they eventually cease proliferating in a state 
referred to as crisis [95–97]. A small number of 
cells within the population may acquire the ability 
to escape from crisis and form an immortalized 
cell line. In all such cell lines examined, escape 
from crisis has been shown to be associated with 
activation of a telomere maintenance mechanism. 
Viral oncoproteins can bind to multiple other 
cellular proteins [92, 98], including several tran-
scription factor complexes involved in hTERT 
transcription regulation [94]. For example, hu-
man papilloma virus E6 protein, via direct bind-
ing, increases c-MYC efficiency in activating 
the hTERT promoter and, on the other hand, 
E6 is able, through its association with E6AP, to 
promote the degradation of the hTERT promoter 
transcriptional repressor NFX1-91 [94]. Usage of 
both viral oncogene and hTERT to induce immor-
talization has also been reported. For instance, 
pre-adipocytes, bone marrow stromal cells and 
ovarian surface epithelial cells were immortal-
ized by introduction of HPV E7 and hTERT [96]. 
Mechanistically, thus, process of immortalization 
induced by viruses corresponds to a process of cell 
cycle checkpoint proteins inactivation (pRB and/
or p53) and restoration of telomerase activity re-
sulting in telomere ends stabilization. 
Ectopic expression of hTERT alone in pre-
senescent or still dividing cells can effectively 
Schematic representation of pRB and p53 signaling 
pathways. p16INK4A inhibits CDK4 and CDK6 
preventing interaction with D-cyclins. CDK4 and 
CDK6 phosphorylate pRB leading to a partial loss of its 
ability to repress the E2F. When pRB-E2F suppressive 
interaction is relaxed, E2F transactivates genes involved 
in G1/S transition and in the initiation of DNA 
replication in S phase. CDK2-cyclin E complexes can 
further phosphorylate pRB resulting to complete its 
release from interacting with E2F and, thus, promoting 
S phase progression. P14ARF/p19ARF is an antagonist 
for MDM2 which, in turn, regulates p53 stability 
through its ubiquitin ligase activity. ARF sequesters 
MDM2 resulting in p53 activation and stabilization. 
p53 induces p21CIP1 expression. p21CIP1 associates with 
cyclin D-CDK4/6, E/A-CDK2, and cyclin B-CDK1 
complexes, and has a universal inhibitory activity 
towards these CDKs thereby regulating G1/S transition, 
S and M phases of cell cycle
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immortalize them (Table 2). The native hTERT 
locus is embedded in a large nuclease-resistant 
chromatin domain in most normal human cells 
[97]. As a result, the hTERT promoter is strin-
gently repressed in somatic primary cells. But in 
immortalized and tumor cell lines hTERT is of-
ten up-regulated, and these cells are capable to 
maintain stable telomere lengths by activation of 
a telomere maintenance mechanism; also, there 
is non-telomerase alternative mechanism of telo-
mere maintenance [95–100]. Except cases with 
ectopic hTERT expression, in otherwise immor-
talized (and tumor) cells hTERT gene activa-
tion can occur in several ways probably mutu-
ally complementary to each other: through gene 
amplification; nonreciprocal translocation by 
chromosomal breakage at the hTERT locus and 
subsequent ligation to heterologous sequences by 
non-homologous end joining (NHEJ) mecha-
nisms resulting in the chromosomal rearrange-
ments upstream of its promoter; the activation 
of c-MYC and inhibition of histone deacetylases 
(HDACs) (reviewed in [97]). Hyperoxia or ad-
dition of exogenous H2O2 was shown to induce 
senescence of fibroblasts despite hTERT overex-
pression and exogenous H2O2 prevented hTERT-
dependent immortalization of normal endothe-
lial cells, whereas N-acetylcystein (antioxidant) 
permitted hTERT-dependent immortalization of 
endothelial cells [38]. Indeed, oxidative stress re-
gulates hTERT at many levels, such as its gene ex-
pression, activity, and sub-cellular localization [42]. 
Immortalization of human and rodent cells was 
also achieved by different transcription factors. 
The c-MYC protein is a basic helix-loop-helix 
leucine zipper transcription factor that modulates 
Table 1
Immortalization of human cells by viral genomes/oncogenes
Indications. SV40 – simian polyomavirus; HPV16/18 – human papilloma virus types 16 and 18; Ad5 and 12 – 
adenovirus type 5 and 12. 
Cell type Immortalizing agent Ref.
Astrocytes
HS74BM diploid fetal bone marrow fibroblasts
IMR-90 diploid lung fibroblasts
Ciliary epithelial cells
Fetal liver epithelial cell 
Mammary epithelial cells
Prostate epithelial cells
Tracheal epithelial cells
Uroepithelia cells
Cervical epithelial cells
Epidermal keratinocytes
Epidermal keratinocytes
Esophageal epithelial cells
Foreskin keratinocytes
Gingival keratinocytes
HFE keratinocytes
Mammary epithelial cells
Mammary epithelial cells
Uroepithelial cells (from ureteral uroepithelium)
Urothelial cells (from ureteric or bladder tissue)
WHE-7 fetal fibroblast
Embrionic kidney cells HEK293
Bronchial epithelial cells
Epidermal keratinocytes
SV40 T antigen
SV40
SV40
SV40
SV40 T antigen
SV40
SV40
SV40
SV40
HPV16/18
HPV16
HPV16 E6+E7 
HPV16 E6/E7
HPV16/18/ 31/ 33
HPV16 E6 
HPV16 E7 
HPV16
HPV16 E6+E7 
HPV16 E7 
HPV16 E6+E7 
HPV16 E6
Ad5
Ad12-SV40 fusion genome
Ad12-SV40 fusion genome
[53]
[54]
[55, 56]
[57]
[58]
[59]
[60]
[61]
[62]
[63, 64]
[65, 66]
[67, 68]
[69]
[70, 71]
[72]
[73]
[74]
[75]
[76]
[77]
[72]
[78]
[79]
[80]
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Table 2
Molecular characteristics of immortalized human cell lines
Indications. RPE-340 – retinal pigment epithelial-340 cells; MDAH 087 – skin fibroblasts derived from a 
patient with Li-Fraumeni syndrome; Y-27632 – Rho kinase (ROCK) inhibitor; 4-NQO  4-nitroquinoline 1-ox-
ide; ALT – alternative telomere maintenance mechanism; «Ĺ» – overexpressed; «Ļ» – downregulated; «+» – 
unchanged level; * for hTERT – overexpressed; «–» – undetected; N/A – not analyzed.
Cells Immort. agent p16INK4A pRB p53 p21CIPI hTERT* Ref.
Adenoid epithelial 
cells and foreskin 
keratinocytes
Ameloblastoma 
cells
BJ fibroblasts,
RPE-340 cells
BJ fibroblasts
Cen3 fibroblasts
Esophageal epithe-
lial cells
Foreskin fibroblasts
Gingival and perio-
dontal ligament 
fibroblasts
Dermal keratino-
cytes
Mammary epithe-
lial cells
Epi gingival kera-
tinocytes
Esophageal epithe-
lial cells
Mammary epithe-
lial cells
WHE-7 fetal fibro-
blasts
Foreskin fibro-
blasts
Prostate epithe-
lial cells
Mammary epithe-
lial cells
Oral keratinocytes
Foreskin keratino-
cytes
KMST-6 fibroblasts
MDAH 087 skin 
fibroblasts
OUMS-24F fibro-
blasts
hTERT
hTERT
hTERT
hTERT
hTERT
hTERT
hTERT
hTERT
hTERT
hTERT
HPV E6
HPV16 E6/E7
HPV16 E6 + E7
HPV16 E6
c-MYC
c-MYC
ZNF217
Cyclin D1 + domi-
nant-negative p53
Y-27632
60Co
Aflatoxin B1/X-rays
4-NQO
–
–
 +/–
N/A
Ļ/ –
Ļ
Ļ deletion
–
–
–
–
Ĺ
N/A
–
+
–
N/A
N/A
+
–
–
+
+ hyper
phosphorylated
N/A
+
+ unaffected
N/A
+ unaffected
Ĺ
+ hyper
phosphorylated
+ hyper
phosphorylated
N/A
E2F1 elevated
+ hyper
phosphorylated
Ļ
Ļ
+ hyper
phosphorylated
N/A
N/A
+ unaffected
N/A
N/A
+ hyper 
phosphorylated
+ hyper
phosphorylated
+ hyper
phosphorylated
+
+
+
+
+ mutated
+ 
+/Ļ mutated 
N/A
+
+
N/A
Ļ
Ļ
N/A
+
+
+ 
+
mutated
+
N/A
+
mutated
N/A
+
+
N/A
N/A
Ļ
Ļ
+/–
N/A
N/A
+
Ļ
Ĺ
Ļ
Ļ
+
+
N/A
N/A
N/A
Ļ
Ļ
Ĺ
+
+
+
+
+
+
+
+
+
+
+
+
N/A
N/A
N/A
+
+
ALT
+
ALT
ALT
ALT
[81]
[82]
[83]
[84]
[24]
[69]
[85]
[72]
[86]
[87]
[72]
[69]
[75]
[72]
[88]
[89]
[90]
[91]
[28]
[72]
[72]
[72]
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expression of a cohort of genes, including those 
that function to promote cell growth and cell cy-
cle entry [88, 101]. c-MYC up-regulates certain 
cyclin-dependent kinases (CDK4) and cyclins 
(A, B1, D1, D2, and E), and represses cycline-
dependent kinase inhibitors (p15INK4B, p21CIP1, 
and p27KIP1) [48, 101, 102]. Mechanisms can be 
direct or indirect: for example, c-MYC directly 
binds to the cyclin B1 promoter, but optimal in-
duction of expression occurs only when p53 is 
concurrently inactivated [102], whereas cyclin D1 
expression is positively regulated through MYC/
miR-378/TOB2/cyclin D1 functional module in 
human mammary epithelial cells [103]. p21CIP1 
expression is regulated both negatively and posi-
tively by c-MYC [104]. Induction of p21CIP1 by 
c-MYC overexpression was p53-dependent in nor-
mal human and mouse fibroblasts and was associ-
ated with G2 arrest, whereas, inversely, c-MYC 
repressed p21CIP1 transcription in p53-null mouse 
cells and in a human adenocarcinoma cell line 
[105]. Moreover, the hTERT promoter contains 
the MYC binding site (E-box) and is a direct tran-
scriptional target of c-MYC [106]. c-MYC expres-
sion was reported to result in successful immor-
talization of rat kidney cells [22], mouse neural 
precursor cells [107], human neural stem cells (by 
v-MYC and c-MYC T58A mutant) [49], prostate 
epithelial cells [89], and foreskin fibroblast cells 
[88]. Interestingly, foreskin fibroblast cells had in-
creased levels of p16INK4A and p53 and functional 
both p16INK4A–pRB (pRB phosphorylation was 
reduced) and p53–p21CIP1 parthways. Prostate 
epithelial cells preserved functional p53-p21CIP1 
pathway and had elevated p16INK4A but, never-
theless, pRB phosphorylation was maintained. 
Moreover, c-MYC allowed to tolerate ectopically 
overexpressed p16INK4A in prostate epithelial cells, 
whereas p16INK4A overexpression in foreskin fibro-
blast resulted in senescence. Foreskin fibroblast 
cells also showed epigenetically silenced p14ARF 
(unfortunately, p14ARF status was not analysed in 
prostate epithelial cells). Rodent cells immortal-
ized by c-MYC characteristically inactivate the 
ARF–p53–p21CIP1 pathway by loss of either func-
tional p53 or 19ARF [88]. p14ARF/p19ARF is unique 
among c-MYC regulators. It selectively inactivates 
the hyperproliferative and transforming func-
tions of c-MYC without affecting normal cell 
cycle progression or preventing c-MYC-mediated 
apoptosis [108]. Thus, p53 or p14ARF/p19ARF in-
activation is likely beneficial in cells immortalized 
by c-MYC. 
Other transcription factor BMI1, a member 
of the Polycomb group of transcriptional repres-
sors [109], was initially identified as an oncogene 
that cooperates with c-MYC in lymphomagenesis 
[110]. Moreover, BMI1 is positively regulated by 
c-MYC [37]. It was reported that overexpression 
of BMI1 down-regulated p16INK4A and p19ARF 
expression in mouse embryonic fibroblasts and 
resulted in their immortalization [96], immortal-
ized primary human mammary epithelial cells 
(HMEC) [111] and nasopharyngeal cells [112]. 
In both latter cases immortalization was accom-
panied by telomerase activation. BMI1 caused 
the bypass of replicative senescence in normal 
human oral keratinocytes but did not immortal-
ize them (no hTERT activation) [113]. BMI1 
introduction along with human papilloma virus 
E6 gene but not with E7 immortalized oral ke-
ratinocytes and it was associated with telomerase 
activation [113]. Introduction of BMI1 as well 
as p16INK4A-specific short hairpin RNA into hu-
man epithelial cells derived from skin, mammary 
gland and lung suppressed p16INK4A expression 
and extended cells life span; subsequent intro-
duction of hTERT in these cells resulted in their 
efficient immortalization with following mainte-
nance of near normal diploidy [96]. The reason 
why some cell types become immortalized after 
BMI1 introduction alone, whereas other cells do 
not is unclear. It was speculated that BMI1-in-
duced immortalization mechanism may be tissue-
dependent or because the cultured cells already 
underwent critical steps towards immortalization 
[113]. The mechanism whereby BMI1 promotes 
evasion of senescence involves, among other tar-
gets, transcriptional silencing of CDKN2A (cy-
clin-dependent kinase inhibitor 2A, which en-
codes both p16INK4A and p14ARF) and CDKN2B, 
which encodes p15INK4B [42, 110, 114]. 
Transcription factor ZNF217 was able to im-
mortalize human primary HMECs disturbing 
ARF-p53-p21CIP1 pathway [90]. ȕ-Catenin, a 
member of the Armadillo (ARM) repeat protein 
superfamily, activates transcription of target genes 
primarily by associating with the T cell factor/lym-
phoid enhancer-binding factor (TCF/LEF) family 
[115, 116]. Expression of ȕ-catenin immortalized 
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primary mouse melanocytes directly repressing the 
expression of p16INK4A by binding to its promoter 
[117]. Other well known targets of ȕ-catenin are 
c-MYC and cyclin D1 [115]. 
In fact, all mentioned targets of discussed tran-
scription factors are only the «top of an iceberg». 
It was established that c-MYC regulates a total 
of 1469 target genes in HeLa cells and human 
primary fibroblasts [118], ȕ-catenin in HCT116 
colorectal carcinoma cells directly bound in vivo 
to more than 400 target genes [115].  ZNF217 was 
shown to target 103 genes in breast cancer cell line 
MCF7, 44 genes in colon cancer cell line SW480, 
and 101 genes in teratocarcinoma cell line Ntera2 
[119]. Moreover, NF-țB, STAT3, ERȕ, JUN, ELK4, 
CEBP, and ETS1 were found among transcrip-
tional regulator genes up-regulated by c-MYC 
in human B cell line P493 [120], and EPAS1, 
ERF, FHL2, JUN, MNT, MYT1, RPO1-2, SOX4, 
TEAD4, TIEG1, and ZFP28 in pancreatic ȕ-cells 
[121], which, in turn, regulate additional gene 
cohorts resulting eventually in global change in 
gene expression. C-MYC can regulate overall up 
to 10–15 % of all genes [120, 122], among which 
there are those regulating replication and repara-
tion in S phase and chromosome separation dur-
ing M phase [121–124]. 
Spontaneously immortalized cells emerge at 
an extremely low frequency (about 10–7) during 
crisis in vitro [85, 97], but show the same gen-
eral changes in cell cycle checkpoint pathways 
as all otherwise immortalized cells [125–127]. 
Thus, overwhelming majority of immortalized 
cells irrespective of «immortalizing agent» do not 
express p16INK4A cell cycle suppressor and this 
correlates with pRB hyperphosphorylation (inac-
tivation) (Table 2). Indeed, it has been estimated 
that more than 70% of human immortalized and 
cancer cell lines lack functional p16INK4A due to 
promoter methylation, mutation, or homozygous 
deletion. In many instances the deletions affect 
both p16INK4A and p14ARF/p19ARF, but a substan-
tial proportion of the missense mutations exclu-
sively affect p16INK4A, suggesting that p16INK4A 
itself plays significant and non-redundant role in 
tumor suppression [128]. Spontaneous reduction 
in p16INK4A expression due to promoter methyla-
tion (most often) or otherwise mechanisms during 
in vitro propagation of normal primary cells has 
been documented, for example, in HMEC [96, 
129], fibroblasts derived from lung [96], human 
keratinocytes [96, 130], and human astrocytes 
[34]. Molecular mechanism of p16INK4A gene in-
activation by epigenetic deregulating methylation 
during progression from primary cells to immor-
talized and pre-malignant cells is complex; it is 
under intensive investigation and may be differ-
ent in mouse and human cells [128, 131–137]. 
Nevertheless, in contrast to frequent loss of 
p16INK4A expression in vitro, another well doc-
umented fact is that p16INK4A is overexpressed 
in certain samples of different cancer types. In 
tumors increased p16INK4A expression correlates 
statistically with RB loss of heterozygosity [138]. 
In spite of being tumor suppressor, overexpres-
sion of p16INK4A, nevertheless, correlates with a 
poor prognosis and seems to be an unfavorable 
prognostic indicator [138].
ARF–p53–p21CIP1 pathway is likely less critical
for immortalization of human cells than 
p16INK4A–pRB, because approximately in a half 
of analyzed works it was apparently functional 
(Table 2). Moreover, Odell et al. [139] exam-
ined more than a hundred spontaneously im-
mortalized MEF cell lines and found that at 
least half of them had neither a p53 mutation 
nor loss of p19ARF. Nevertheless, it is neces-
sary to take into account that analysis of ARF-
p53-p21CIP1 pathway in most works (where it 
was shown functional) was performed once in 
certain population doubling (PD), but it could 
be inactivated later. For instance, hTERT im-
mortalized cen3tel fibroblasts up to 108 PD had 
wild-type p53 sequence, whereas at late PDs (165 
and 366 PDs) had a mutation in codon 161 [24].
Thus, it is possible to conclude that for suc-
cessful immortalization cells must overcome se-
nescence by inactivating p16INK4A–pRB and /or 
ARF-p53-p21CIP1 and crisis by maintaining their 
telomeres by activation of hTERT expression 
or by an alternative mechanism for lengthening 
telomeres (ALT) [99, 100]. However, it needs to 
keep in mind that every oncogene/«immortalizing 
agent» introduced into a cell has a great number 
of targets and multidirectional effects rather than 
being one-way agent. Thus, the process of im-
mortalization is not simply a number of well de-
fined events like inactivation of cell cycle nega-
tive regulators and activation of telomerase but, 
instead, is associated with karyotype/genome ab-
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normalities (aneuploidy/gain or loss of additional 
chromosomes, translocations, deletions and am-
plifications) and, as a consequence, with global 
changes in gene expression [165]. All immortal-
ized cells have abnormal karyotypes irrespectively 
of «immortalizing agent» (Table 3).
Also, significant changes in global gene ex-
pression can be reached through aberrant meth-
ylation of promoters. In HMECs during im-
mortalization global aberrant DNA methylation 
changes occured in a stepwise fashion [129]. The 
first aberrant DNA methylation step coincided 
with overcoming stasis, and resulted in few to 
hundreds of changes, depending on how stasis 
was overcome (stress-inducing serum-free me-
dium, benzo(a)pyrene or p16INK4A shRNA). A 
second step coincided with crisis/immortaliza-
tion and resulted in hundreds of additional DNA 
methylation changes regardless of the immortal-
ization pathway [129].
All together, it explains why across cell types 
and model systems genes in the cell cycle path-
way, cytoskeletal genes, IFN pathway, IGF path-
way, MAP kinase pathway, and oxidative stress 
pathway were identified as regulators of senes-
cence/immortalization [41, 166]. It is worth no-
ticing that virus oncoproteins induce more pro-
found karyotype changes because of simultaneous 
ablation of pRB and p53 pathways, inactivation 
of which is directly linked with aneuploidy/poly-
ploidy. In contrast, hTERT alone immortalized 
cells are suggested to be apparently genetically 
stable frequently showing near diploid karyotypes 
with lower abnormalities than otherwise immor-
talized cells [47, 142, 143, 147, 167–171]. It is 
clear that telomerase introduction into a cell can 
Table 3
Karyotype abnormalities in immortalized cells
Immortalizing agent Ref. Immortalizing agent Ref.
Cells immortalized by hTERT 
Human adenoid epithelial cells  and 
foreskin keratinocytes
Human fibroblasts from two 
centenarian individuals
Human normal fibroblasts
Sheep fibroblasts
Human bone marrow endothelial cells
Human small airway epithelial cells
Human mammary epithelial cells
Human myometrial and uterine 
leiomyoma cells
Swine umbilical vein endothelial cells
Human mesenchymal stem cells
Human fetal hepatocytes
Human meibomian gland epithelial 
cells
Cells immortalized by SV40 T 
large antigen
Rabbit kidney epithelial cells
Human corneal epithelial cells
Human gingival keratinocytes
Human nasopharyngeal epithelial cells
Human bronchial epithelial cells
Human mammary epithelial cells
[81]
[140]
[83, 84, 
141, 142]
[143]
[144]
[145]
[46]
[146]
[47]
[147]
[148]
[149]
[150]
[151]
[152]
[153]
[154]
[155]
Cells immortalized by HPV16/18 E6/E7
Human epidermal keratinocytes
Human smooth muscle cells
Human nasopharyngeal epithelial cells
Human extravillous cytotrophoblasts
Human bronchial epithelial cells
Spontaneously immortalized cells
MEFs
Syrian hamster embryo cells
Human epidermal cells
Human keratinocytes
Murine neural crest-derived corneal 
progenitor cells
Immortalized by otherwise ways
Mouse embryos cells by v-SIS or K51 
oncogenes
Human mesenchymal stem cells by E6/E7 
plus hTERT or BMI1, E6 plus hTERT
Human meibomian gland epithelial cells by 
SV40 LT antigen plus hTERT
Human bronchial epithelial cells by hTERT 
plus CDK4 or HPV16 E6/E7 
Human bronchial epithelial cells by BMI1 
plus hTERT
Human prostate epithelial cells by c-MYC
Oral keratinocytes by cyclin D1 plus mutant p53
[156]
[157]
[153]
[158]
[159]
[160]
[161]
[125]
[162]
[126]
[163]
[147]
[149]
[159]
[164]
[89]
[91]
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stabilize telomeres preventing numerous chromo-
somal aberrations occuring via telomere dysfunc-
tion and the breakage-fusion-bridge mechanism 
[165]. Nevertheless, although BMI1 and hTERT 
immortalized human embryonic stem cells at 
passage 40 [172], as well as hTERT immortalized 
human neural progenitor cells isolated from the 
ventral telencephalons of first trimester embryos 
after more than 40 passages (80–120 PD) [170] 
had normal karyotypes, in contrast, hTERT im-
mortalized bone marrow endothelial cell clones 
showed numerous abnormalities after 75 PD 
(more than 160 days) [144]. Interestingly, mass 
culture of these cells at 65 PD (120 days) had 47 
chromosomes without any structural abnormali-
ties and served this karyotype at 135 PD [144]. 
Also, prolonged cultivation of telomerase-immor-
talized human fibroblasts led to a premalignant 
phenotype, although hTERT-immortalized cells 
behaved similarly to primary cells during the first 
150 PDs [141]. The possible pitfall of «normal» 
or near diploid karyotypes of hTERT immortal-
ized cells can result from exploiting conventional 
cytogenetic techniques for karyotyping, which do 
not allow detecting the subchromosomal aberra-
tions. In contrast, for example, SNP and CGH 
arrays revealed multiple genomic abnormalities 
in tumors with near diploid katyotypes.
How do immortalized and tumor cells become 
aneuploid? p53, a well known «genome safeguard», 
plays multiple roles in maintaining genomic stability 
in somatic cells. Loss of p53 functions promotes on-
cogenesis by inducing chromosomal instability and 
aneuploidy [173-176] and enabling efficient accu-
mulation of genetic mutations [177]. Loss or muta-
tional inactivation of p53 results in a high frequency 
of centrosome amplification in part via allowing the 
activation of CDK2-cyclin E (as well as CDK2-
cyclin A), which is a critical factor for the initiation 
of centrosome duplication [178]. It also allows im-
mature escaping from cell cycle G2 checkpoint ar-
rest through inability of p21CIP1 to inactivate CDK2, 
and this leads to reinforcement of CDK2-dependent 
NF-Y phosphorylation and NF-Y dependent tran-
scription of the cell cycle G2-regulatory genes, in-
cluding CDK1, CDC25, cyclin A and B [179].
There is also a link between pRB inactiva-
tion, cell aneuploidy and chromosome instabil-
ity (CIN). Aneuploidy and CIN results from 
persistent defects in mitotic fidelity, and several 
mechanisms have been described that cause cells 
to missegregate whole chromosomes [176, 180, 
181]. More than 50 proteins are able to trigger 
polyploidy/aneuploidy when are appropriately 
misregulated (mutation, depletion, knockdown 
or overexpression) [182]. If the dosage of any 
one of many proteins involved in ensuring chro-
mosome segregation fidelity is disrupted by the 
missegregation of the chromosome carrying that 
gene, the resulting imbalance can further com-
promise chromosome segregation accuracy [176]. 
Importantly, pRB-E2Fs pathway directly regu-
lates genes involved in bipolar spindle formation, 
chromosome-spindle association, chromosome 
cohesion, and the spindle assembly checkpoint 
(SAC) [183]. Acute pRB suppression in IMR90 
cells [184], HCT116 cells [185], primary hu-
man fibroblasts [186], mouse embryonic fibro-
blasts [180], and mouse adult fibroblasts [187] 
caused misregulation of chechpoint genes [180, 
185, 186] and, as a consequence, gave rise to 
centrosome amplification, multipolar spindles, 
anaphase bridges, lagging chromosomes, and mi-
cronuclei harbouring whole chromosomes result-
ing in polyploidy/aneuploidy and cancerogenesis 
[180, 184–188]. Moreover, pRB influences mi-
totic chromosome condensation in E2F-inde-
pendent manner, and loss of pRB function can 
influence chromosome loss irrespectively of pro-
liferation [189]. pRB can interact with the con-
densin II subunit CAP-D3, and this interaction is 
necessary for chromosome compaction in mitosis 
[189]. pRB depletion compromises centromeric 
localization of CAP-D3/condensin II and chro-
mosome cohesion, leading to an increase in in-
tercentromeric distance and deformation of cen-
tromeric structure [181]. These defects promotes 
merotelic attachment (occurs when one kineto-
chore is attached to both mitotic spindle poles), 
resulting in failure of chromosome congression 
and an increased propensity for lagging chromo-
somes following mitotic delay [181]. 
In contrast to pRB, p107 and p130 (also 
members of retinoblastoma family) are rarely 
found inactivated in human tumors [190], and 
this fact determined predominant research on 
pRB, but it hardly proves the unique importance 
of pRB in cell cycle regulation. Equally weighty 
roles of p107 and p130 may well be masked by 
a functional redundancy that they have with one 
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another. Such redundancy would drastically re-
duce the likelihood of their elimination from tu-
mor cell genomes during tumor progression [191]. 
Indeed, these proteins are part of a «tumor-sur-
veillance» mechanism and can suppress tumori-
genesis [190, 192–194]. 
Another consequence of pRB and p53 path-
ways deregulation is compromised DNA damage 
surveillance and repair. More than 70 genes have 
been identified that have roles in DNA damage 
surveillance and repair [195], and many of them 
are regulated by pRB and p53 [183, 195]. 
pRB and/or p53 pathways deregulation and 
hTERT expression (or ALT) are markers and indis-
pensable conditions of immortalization. Deregu-
lated pRB and/or p53 pathways inevitably leads 
to numerical and structural chromosome aber-
rations. A cell attains immortality by a global 
change in gene expression, which accompanies 
karyotype changes. Although a few common chro-
mosome aberrations might have been observed in 
different immortalized cell, karyotype changes, 
in general, have stochastic nature. Immortalized 
cells with aberrant karyotypes are prone to malig-
nant transformation. 
Transformation. Cancer cells display several
hallmarks that can be distinguished from those of 
normal counterparts. These include immortaliza-
tion (bypass of senescence), evasion of apoptosis,
immune destruction and anti-growth signals, 
growth factor independence, reprogramming of ener-
gy metabolism (enhanced glycolysis), anchorage-
independence, resistance to contact inhibition, mi-
gration, invasion/degradation of matrix components, 
angiogenesis, metastasis, inflammation, and geno-
me instability, which generates the genetic diver-
sity accelerating acquisition of all listed hallmarks 
[31, 196]. In addition to cancer cells, tumors ex-
hibit another dimension of complexity: they contain 
a repertoire of recruited, ostensibly normal cells 
that contribute to the acquisition of hallmark traits 
by creating the «tumor microenvironment» [196].
Cancer genes are often classified according to 
whether they function in a dominant or recessive 
manner at the level of the cancer cell. Dominant 
cancer genes (also known as oncogenes) require 
only one of the two parental alleles present in 
a normal cell to be mutated, and the encoded 
protein is usually constitutively activated by the 
mutations. Recessive cancer genes (also known 
as tumor suppressor genes) require mutation of 
both parental alleles, and these usually result in 
inactivation of the encoded protein. More than 
80 % of the currently known cancer genes are 
dominantly acting [3]. Census of cancer genes 
lists 467 genes (data on December 2011, www.
sanger.ac.uk/genetics/CGP/Census), which are 
supposed to be causally implicated in cancer de-
velopment when appropriately changed (point 
mutations, deletions, translocations or ampli-
fications) [197]. However, studies in mice have 
suggested that more than 3000 genes, when ap-
propriately altered, may have the potential to 
contribute to cancer development (see reference 
in [198]).
The process of cellular transformation has been 
intensively studied in vitro using cell-culture tech-
niques. Most research works on this issue satisfy four 
criteria: the cells are immortalized, i.e., can grow 
indefinitely in culture; the cells can efficiently form 
colonies in soft agar; the cells can develop tumor in 
immunodeficient mice; the xenograft or orthotopic 
tumor in the mouse shows malignant histology to 
exclude a pseudo-tumor or a benign tumor [267]. 
Actually, there are a few interesting outliers. For 
example, cells obtained by stable overexpression of 
cyclooxygenase 1 in spontaneously immortalized 
human umbilical vein endothelial cells underwent 
contact inhibition, failed to grow under anchor-
age-independent conditions but grew aggressively 
as tumors in mice [202]. Human primary foreskin 
fibroblasts in which E1A+H-RASV12+MDM2 were 
introduced, although able to form colonies in soft 
agar and tumors in nude mice, were not immor-
tal and, if maintained in culture for an extended 
period of time (40–50 generations), underwent a 
crisis phase characterized by dramatically reduced 
proliferation and adoption of a senescent pheno-
type [10]. Cells were telomerase-negative, only few 
of them eventually survived this phase and these 
cells became telomerase-positive [10]. 
MAPK and PI3K-AKT signaling pathways in 
transformation: a double-edged sword. One prom-
inent hallmark of transformed in vitro cells irre-
spectively of transforming agent is upregulation 
of RAS-dependent extracellular signal-regulated 
kinases 1 and 2 (ERK1/2) mitogen-activated 
protein kinase (MAPK) pathway, phosphoinosit-
ide-3-kinase (PI3K)-mammalian target of ra-
pamycin (mTOR)-AKT pathway and overex-
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pression of CDKs/cyclins. Actually, besides 
MAPK and PI3K/AKT signaling, other path-
ways can also be activated. Nevertheless, RAS-
dependent extracellular signal-regulated kinase 
1/2 (ERK1/2) mitogen-activated protein (MAP) 
kinase [268–270] and phosphoinositide-3-ki-
nase (PI3K)-mammalian target of rapamycin 
(mTOR)-AKT cascades [271] are the key signal 
transduction pathways responsible for integrat-
ing the different environmental signals and re-
laying the information to the cell cycle control 
system. Both these pathways are hyperactivated 
frequently in transformed cells in vitro and tu-
mors in vivo, and are involved in regulation of all 
aspects of normal and tumor cell biology (e.g., 
cell growth, proliferation, apoptosis, migration, 
invasion etc). 
As it is reviewed in [268-270], ERK1/2 are 
required for cyclin D1 expression via regulation 
of FOS family members and c-MYC transcrip-
tion factors, as well as inhibition of TOB1 and 
JUND, cyclin D1 expression negative regula-
tors. The ERK pathway may assist in both the 
assembly and stabilization of cyclin D1-CDK4/6 
complexes via HSC70. There are also a few re-
ports implicating MAPK pathway in the regu-
lation of cyclin D2 and cyclin D3 expression. 
ERK activity is required for proper nuclear 
translocation of CDK2, and in the nucleus ERK 
regulates phosphorylation of a CDK2 activat-
ing site. ERK can phosphorylate two of four 
phosphorylation sites of the cytoplasmic reten-
tion sequence of cyclin B1, which are neces-
sary for nuclear localization of cyclin B1. ERK 
futher contributes to CDK1-cyclin B activation 
via RSK/MYT1/CDK1-cyclin B pathway. The 
RAS-ERK signaling pathway is involved in the 
mitogen-induced downregulation of p27KIP1. The 
degradation of p27KIP1 at the G1/S transition 
depends on the accumulation of cyclin E and 
concomitant activation of CDK2, events that 
are conditional on earlier activation of cyclin D-
CDK4/6 complexes by the ERK pathway. 
Activation of ERK markedly enhances c-
MYC protein stability, which can transcription-
ally upregulate expression of certain cycline-
dependent kinases (CDK4) and cyclins (A, B1, 
D1, D2 and E), and represses cyclin-dependent 
kinase inhibitors (p15INK4B, p21CIP1 and p27KIP1) 
[48, 101,102, 272]. ERK1/2 dislodge pRB from 
its interaction with lamin A, thereby facilitating 
its rapid phosphorylation and consequently pro-
moting E2F activation and cell cycle entry [273]. 
Pyrimidine nucleotides serve as essential precur-
sors for the synthesis of RNA and DNA, phos-
pholipids, UDP-sugars and glycogen [268, 270]. 
The rate-limiting step in the pyrimidine pathway 
is catalysed by the carbamoyl-phosphate synthe-
tase enzyme, which is part of the large multifunc-
tional protein CAD [268, 270]. ERK2 directly 
phosphorylates CAD activating it. ERK may im-
pact on global protein synthesis through direct 
regulation of ribosomal gene transcription [268].
Over a hundred putative AKT substrates have 
been reported. Targets among cell cycle regulating 
proteins are reviewed in [43, 274, 275]. GSK3-
mediated phosphorylation of cyclin D and cy-
clin E and the transcripton factors c-JUN and 
c-MYC, which all play a central role in the G1-
to-S phase cell-cycle transition, targets them for 
proteasomal degradation. Phosphorylation and 
inhibition of GSK3 by AKT enhances the sta-
bility of these proteins. AKT reduces p21CIP1 
protein level through downregulation of p53-
mediated transcription and activation of MDM2, 
and inhibits p27KIP1 expression via inactivation 
of FOXO family of transcription factors. AKT 
phosphorylates both p21CIP1 and the p27KIP1 cy-
clin-dependent kinase inhibitors leading to their 
cytosolic sequestration and phosphorylates and 
deactivates pRB leading to the activation of E2F. 
AKT induces p27KIP1 degradation via GSK3ȕ/c-
MYC/p27KIP1.
Aberrant activation of mTORC1 is a common 
molecular event in a variety of cancers [276, 277]. 
Activation of the AKT and ERK pathways acts 
in a synergistic manner to promote mTORC1 
signaling through phosphorylation of a tuberous 
sclerosis complex 2 (TSC2), GTPase activator 
protein (GAP), leading to the disruption of the 
TSC1-TSC2 complex as an inhibitor of RHEB, 
which in turn regulates mTORC1. AKT phos-
phorylates residues of TSC2 distinct from those 
phosphorylated by ERK [278]. Furthermore, the
kinase RSK, a direct downstream substrate of ERK,
can also phosphorylate TSC2 to inhibit the func-
tion of TSC1/TSC2 complex [270]. The S6K1 
and 4E-BP1/eIF4E pathways represent critical 
mediators of mTORC1-dependent cell cycle con-
trol [279, 280] by promoting the cap-dependent 
48 ISSN 0564–3783. Öèòîëîãèÿ è ãåíåòèêà. 2012. ¹ 2
A.A. Stepanenko, V.M. Kavsan
translation of many target mRNAs, including 
those encoding cyclins and c-MYC [274, 281]. 
mTORC2 also contributes to cell size and cell 
cycle regulation via AKT activation and, thus, 
contributing to TSC2 inactivation [275]. 
Nevetheless, it should be noted that the induc-
tion of cell cycle arrest by hyperactivation of the 
ERK1/2 pathway does occur in some cell lines 
and is frequently observed in non-immortalized 
primary cells. Expression of activated forms of 
RAS, RAF or MEK1 was shown to elicit cell 
cycle arrest in primary fibroblasts, Schwann cells, 
hepatocytes, T lymphocytes, keratinocytes, astro-
cytes, and epithelial intestinal cells (reviewed in 
[268]). Notably, the proliferation arrest observed 
in primary fibroblasts, astrocytes and epithelial 
intestinal cells is permanent and phenotypi-
cally related to cellular senescence [268]. This 
phenomenon is not restricted to MAPK path-
way. AKT overexpression induced senescence of 
primary and immortalized esophageal epithelial 
cells [282], primary MEFs [283], primary human 
aortic endothelial cells, human dermal microvas-
cular endothelial cells, and human umbilical vein 
endothelial cells [284, 285]. Moreover, senes-
cence can be triggered in human cells by overex-
pression of E2F1/3, CDC6, MOS or deletion of 
PTEN and NF1 (reviewed in [36]). 
A robust and prolonged activation of ERK1/2 
causes G1 arrest due to long-term p21CIP1 in-
duction [286, 287] and CDK2 inhibition and 
also induces the expression of p53 and the CDK 
inhibitors p16INK4A and p15INK4B in certain cell 
lines [36, 268]. Indeed, ERK pathway can induce 
p21CIP1 transcription [287], translation [288], 
mRNA stabilization [289] and block proteasome-
mediated p21CIP1 degradation [287]. Constitutive 
activation of AKT promotes senescence-like ar-
rest of cell growth via a p53/p21CIP1-dependent 
pathway and this action is at least partly medi-
ated by the forkhead transcription factor [284]. 
On the other hand, hyperactivated MAPK 
and PI3K-AKT pathways were documented in 
most, if not all, tumors and elevated p21CIP1 ex-
pression was highlighted, for example, in rectal 
stromal tumors [290], lung adenocarcinomas 
[291], bladder tumors [292], colorectal carci-
nomas [293], ependymomas and astrocytomas 
[294], hepatocellular carcinomas [295], choroidal 
melanoma tumors [296], and rhabdomyosarcoma 
cells [288]. Importantly, in these cancers p21CIP1 
expression was associated with tumor malignancy 
and poor prognosis but not with long-term sur-
vival as it was expected. 
Thus, oncogene-induced senescence occurs in 
primary cells, some immortalized and in benign 
but not in advanced tumors. It suggests that tu-
mor cells gain resistance to p21CIP1-mediated 
scenesence and inhibition of CDK/cyclin com-
plexes. Oncogene-induced senescence can be 
bypassed by inactivating pRB and p53. Accord-
ingly, if pRB and/or p53 are inactivated in a cell 
before an oncogenic event, senescence should be 
averted what is supported by numerous in vivo 
mouse modeling studies and by genetic analysis 
of human tumors [36]. Moreover, RB deficiency 
sharply increases the ability of RAS to bind gua-
nine nucleotides, resulting in its activation [297].
Importantly, p21CIP1 (and p27KIP1 to a lesser 
degree) functions as an assembly- and activity-
promoting factor for cyclin D-CDK4, cyclin 
E/A-CDK2, and cyclin B-CDK1 complexes 
when p21CIP1 level is below a certain threshold, 
after which the presence of excess p21CIP1 be-
comes inhibitory. Stoichiometry of p21CIP1 is 
critical to allow or inhibit kinase activity [104, 
286]. When one p21CIP1 molecule is binding to 
cyclin-CDK, the complex is catalytically active, 
while binding of several p21CIP1 subunits inhibits 
the complex. Thus, simultaneous overexpression 
of CDKs/cyclins with p21CIP1 would create more 
active complexes fostering cell cycle progression 
and resistance to antimitotic stimuli. 
Interestingly, in contrast, loss or decrease of 
cyclin dependent kinase inhibitor p27KIP1 is com-
monly seen in many human cancers as lung, breast 
and prostate adenocarcinomas, gastrointestinal 
malignancies, brain tumors, and lymphoprolifera-
tive neoplasms [298]. Level of p27KIP1 in epithe-
lial cancers correlates with the pathologic tumor 
grade: high-grade, poorly differentiated tumors 
showing significantly lower p27KIP1 protein than 
their well-differentiated counterparts [298]. Thus, 
selection of tumor cells against p27KIP1 is likely 
beneficial, and p27KIP1 has less profound role in 
CDK-cyclin complex assembly than p21CIP1.
Karyotype evolution, selection and tumorige-
necity. Accoding to the Duesberg's evolutionary 
chromosomal cancer theory [299–302], «activated 
oncogenes induce neoplastic transformation by 
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inducing random aneuploidy. Aneuploidy destabi-
lizes the karyotype by unbalancing teams of proteins 
that segregate, synthesize and repair chromosomes in 
proportion to the degree of aneuploidy. Aneuploidy 
initiates and maintains karyotypic evolutions 
automatically because of the inherent instability 
of aneuploidy. Occasionally, rare cancer-causing 
karyotypes evolve stochastically. These cancer-
causing karyotypes are then stabilized against 
the inherent instability of aneuploidy by selection 
for transforming function within narrow clonal limits 
of variation. Flexibility and heterogeneity of cancer 
karyotypes is the basis for the further, spontaneous 
evolutions that are known as tumor progression, such 
as metastasis and drug resistance». Most oncogenes 
deregulate DNA replication, centrosome amplification 
and chromosome segregation and lead to formation 
of DNA double strand breaks and chromosome 
instability. Indeed, oncogene and carcinogene induced 
chromosome instability is a driving force of cell 
immortalization and tumor evolution (Stepanenko 
and Kavsan, in preparation). For example, activated 
RAS induces DNA double strand breaks in NIH3T3 
fibroblasts within a single cell cycle; other oncogenes, 
including MYC, cyclin E, MOS, CDC25A, E2F1 
and sustained delivery of growth factors have similar 
effects in various cell types and in animal models (re-
viewed in [303]). Importantly, most of experiments 
detecting transforming ability of genes overexpressed 
and/or mutated in tumors (oncogenes) were per-
formed using mouse and human cell lines (Table 4 
and 5), which represent already immortalized cells 
with abnormal karyotypes (poly-/aneuploids with se-
vere chromosome rearrangements) and are prone to 
progress to completely transformed cells under culture 
conditions. 
Human embryonic kidney 293 cells (also of-
ten referred to as 293 cells, HEK 293, or less 
precisely HEK cells) is widely used human cell 
line both for basic molecular studies and as a ve-
hicle for the production of recombinant proteines 
and viruses [304]. Originally named simply «293 
cells» («293» designates a number of experiment), 
they were obtained by exposing human embry-
onic kidney cell culture to mechanically sheared 
fragments of adenovirus type 5 DNA (Ad5) [78]. 
After transformation the cells subcultured more 
than 100 times could be considered as an estab-
lished/immortalized line and contained 4 to 5 
fragments of Ad5 genome [78]. The transform-
ing region of the human adenovirus is within the 
left 11 % of the viral genome encoding E1A and 
E1B proteins which are necessary and sufficient 
for mammalian cell transformation by Ads [305]. 
The integration site of the adenoviral DNA was 
mapped to chromosome region 19q13.2 [305]. 
Adenovirus-induced chromosome aberra-
tions in human cells are well documented fact 
[306, 307]. Bylund et al. [304] performed cyto-
genetic studies on the 293 cells obtained from 
different sources. Karyotype analysis (G-banding 
and spectral karyotyping) showed that 293 cells 
(from ECACC, Salisbury, UK) cultured for less 
than ten days prior to harvesting was near trip-
loid with 62–70 chromosomes/cell and had lots 
of chromosomal abnormalities. No additional 
chromosomal changes were found between 293 
cells and 293aged cells (in culture 6 months, more 
100 PD). Thus, 293 cells exhibit the cytogenetic 
stability during culturing. Another work on 293 
cell karyotype (cells were obtained from ATCC, 
Manassas, VA, USA) also showed triploidy of 
these cells [308] but with only partial overlap in 
chromosome gains/losses comparing with cells 
analysed by Bylund et al. [304]. Interestingly, 
original 293 cells obtained by Graham et al. [78] 
and tested at passage 8 were near-tetraploid and 
retained this ploidy at passage 38. On the other 
hand, it was revealed that 293 cell tumorigenic 
potential correlated with number of passages, 
that is, low-passage cells (less 52 passages) could 
not form tumors in mice in 8 weeks, whereas 
tumorigenicity reached 100% when the passage 
had exceeded 65 (2 Â 107 cells per injection; 10 of 
10 mice had about 0.5 cm3 in size tumors within 
2 weeks, after 4 weeks tumor was as large as 2.0 
Â 1.5 Â 1.3 cm3) [309]. Nevertheless, there is no 
correlation between long-time culturing-induced 
tumorigenesis of parental 293 cells and karyotype 
instability [304, 309]. 
The possible reason why prolonged cultiva-
tion drives tumorigenic potential of parental 
cells might be deduced from investigations with 
NIH3T3 murine fibroblasts, which were used for 
transformation assays much more frequently than 
any other cells (Table 5). NIH3T3 cells were ob-
tained in 1962 as spontaneously immortalized 
cells during long culturing using «3T3 proto-
col» [160]. Rubin documented [310–315] that 
spontaneous transformation of NIH3T3 (also of 
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Table 4
Transformation of human cells
Indications. HMEC – human mammary epithelial cells; SV7tert cells – derived from angiomyolipoma; FoxM1B – 
member of the Forkhead box transcription factor; RPMS1 – ORF of Epstein-Barr virus; PTTG1 – pituitary 
tumor-transforming 1; MutCCK2R – cholecystokinin-2 (CCK2)/gastrin receptor intron 4 retained; ESM1 – 
endocan, dermatan sulfate proteoglycan; CD74 – major histocompatibility complex, class II invariant chain; 
HCCR1 – human cervical cancer oncogene 1; PDX1 – pancreatic and duodenal homeobox-factor 1; ROBO1 – 
a member of round about family of transmembrane receptors.
Cell type Immortalizing agent Transforming agent Ref.
Astrocytes
Barrett's epithelial cells
BJ fibroblasts
cen3tel fibroblasts
Colorectal crypt cells
HUVEC
Embryonic esophageal 
epithelial cells
FHC fetal colon cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
293 cells
HMEC
HMEC
HMEC
HMEC
MCF-10A
MCF-12A
MCF-10A, 12A
MCF-10A
MCF-10A
MCF-10A
MCF-10A
MCF-10A
Oral epithelial cells
Ovarian epithelial cells
Prostatic epithelial cells
SV7tert cells
HPV E6 + E7 + hTERT
hTERT
Primary normal cells
hTERT
hTERT + SV40 large T antigen
Spontaneous
HPV18 E6 + E7
Primary normal cells
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
Ad5
hTERT
Primary normal cells 
hTERT
Primary normal cells
Spontaneous
Spontaneous
Spontaneous
Spontaneous
Spontaneous
Spontaneous
Spontaneous
Spontaneous
E6/E7
SV40 LT + hTERT
SV40
SV40 LT antigen + hTERT
FoxM1B 
H-RASG12V + p53 knockdown
E1A + H-RASG12V + MDM2
Culture propagation/spontaneous
MCLR (cyclic hepatotoxin peptide)
COX1 (cyclooxygenase1)
Culture propagation/spontaneous
MET wt or MET mutated
FAP (fibroblast activation protein)
PTTG1  
RPMS1 
ǻHER2 (ǻ exon 16)
CnB (calcineurin B subunit)
VEGF111, 121, and 165
CCK2R mutated
ESM1 
CD74 
HCCR1 
hBD3 (ȕ-defensin 3)
PDX1 
ROBO1 
SV40 LT and st,  p110D, RASG12V
WNT1
c-MYC transcription factor
MYCT58A
EphA2
ESE1 transcription factor
DB-crystallin 
CD8-IGF-IRȕ chimera
hGH (human growth hormone)
EGFR + c-SRC
HOXA1 transcription factor
HER2V664E
ErbB2
H-RAS mutated or ErbB2
FGF7 (fibroblast growth factor)
PDGF (platelet derived growth factor)
[199]
[200]
[10]
[24]
[201]
[202]
[203]
[25]
[204]
[205]
[206]
[207]
[208]
[209]
[210]
[211]
[212]
[213]
[214]
[215]
[216]
[217]
[26]
[48]
[27]
[218]
[219]
[220]
[221]
[222]
[109]
[223]
[137]
[224]
[225]
[226] 
[227]
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Balb/c 3T3 mouse fibroblasts) cell line in mono-
layer culture is common event especially if cells 
were allowed to reach high density in routine 
passages (transformation of a diploid line of rat 
liver cells is also accelerated by the constraint of 
confluence). It also occurs in low density pas-
sages supplemented with low concentrations of 
serum. If however the cells are kept continuously 
and rapidly multiplying at low density in high se-
rum concentration, not only do they remain non-
transformed but they gradually lose the capacity 
for transformation under standard conditions 
[310–315]. Grown at different growth conditions 
(confluence, concentrations of serum) karyotypes 
of NIH3T3 cells analyzed at different passages 
(24, 253 and 385 passages) showed that although 
the chromosome complement of each of the pas-
sages was near triploid/hypotetraploid (76 ± 2.65,
74 ± 3.2 and 72 ± 2.3, respectively, instead of 
the normal 40 chromosomes in mice), there 
were more marker (i.e., abnormal) chromosomes 
in passage 385 cells than in the earlier passages 
[312]. Moreover, every one of the karyotyped 
cells of each passage was unique in the precise 
distribution of chromosomes. These results sug-
gest that passaging and culture conditions can in-
fluence on aneuploid karyotype of NIH3T3 cells. 
It worth recalling that 293 cells also retained near 
triploid karyotype through more 100 doublings (6 
months in culture) but modal number of chro-
mosomes ranged from 62 to 70, that is, there are 
cell populations inside cell line that differ from 
each other [304]. In fact, genotypic and pheno-
typic variants constantly appear in the cell line 
populations. In addition to the passage number 
and the media, the selection of variants is also 
modulated by the temperature, humidity, and 
CO2 concentration. Some cells can occur to be 
Table 5
NIH3T3 cells transformation
Indications. mAChR – muscarinic acetylcholine receptor; CDC42HsF28L – full GTPase activity but sponta-
neous GTP-GDP exchange; EEF1A2 – protein elongation factor 1A2; EGFR – epidermal growth factor receptor; 
F-LANa – a member of Derlin family; GDo Q205L and GDq Q209L – lack of guanosine triphosphatase (GTPase) 
activity; G6PD – glucose-6-phosphate dehydrogenase; HCCR1 – human cervical cancer oncogene 1; HCCRBP1 – 
human cervical cancer oncogene binding protein 1; IMUP1 and 2 – immortalization-up-regulated protein 1 and 2; 
LIN28 and LIN28B – the RNA-binding proteins that block let-7 precursors from being processed to mature 
miRNAs and consequently derepress let-7 target genes; Matrigel – extract of basement-membrane proteins; 
Midkine – a heparin-binding growth factor; Mina53 – Myc-induced nuclear antigen; PAR - prostate androgen 
regulated; PDGF – platelet-derived growth factor; RET – receptor tyrosine kinase for members of the glial cell 
line-derived neurotrophic factor family; STAT3-C – constitutively dimerizable STAT3. 
Transforming agent Ref. Transforming agent Ref.
mAChR
AKT1myr
AzI (antizyme inhibitor)
BCR-ABL + IL3R 
BI1 (Bax inhibitor 1)
CDC42Hs (F28L)
Cyclin T1
EEF1A2 
EGFR mutant
FGF (fibroblast growth factor)
F-LANa
GDq Q209L, wtGDq, GDo Q205L 
G6PD 
HCCR1 
HCCRBP1
HPV E7 truncated
IMUP1 and 2 
[228]
[229]
[230]
[231]
[232]
[233]
[234]
[235]
[236]
[237–239]
[240]
[241–243]
[244]
[213]
[245]
[246]
[247]
KIT (stem cell factor receptor)
Lin28, Lin28B
Matrigel
Midkine
Mina53 
MUC4 (mucin)
Nanog transcription factor
Ornithine decarboxylase
PAR 
PDGF 
Pleiotrophin
Polyamines
RET mutants
c-SRC + nuclear oncogenes
v-SRC
v-SRC, STAT3-C
14-3-3J
[248]
[249]
[250]
[251]
[252]
[253]
[254]
[255, 256]
[257]
[258, 259]
[260]
[261]
[262]
[263]
[264]
[265]
[266]
52 ISSN 0564–3783. Öèòîëîãèÿ è ãåíåòèêà. 2012. ¹ 2
A.A. Stepanenko, V.M. Kavsan
more physiologically advantaged to grow during 
culture monolayer constrains (e.g. confluence). 
Subsequent selection and clonal propagation of 
such cells can progressively replace the rest more 
growth restrained cells leading eventually to full 
replacement with the cell population with superior 
growth properties [316]. Selection explains why 
culturing 52 passages retained 293 cells growth 
restrained (cells did not form tumors in mice), 
whereas additional only 13 passages were enough 
to make cells fully transformed. To the point, au-
thors stated that 293 cells were propagated as the 
cells grown to a 90 % monolayer [309]. Trans-
formation can arise by the continuous fluctuation 
of growth states within cells, accompanied by the 
progressive selection of those states best suited to 
function under the selecting constraint [310–315]. 
The selection may foster cells carrying alterations 
that confer the capability to proliferate and survive 
more effectively than their neighbors [198]. Cell-
cell contact interactions can conditionally deter-
mine suppression or selection of the neoplastic 
phenotype [315]. It is selection that plays a major 
role in the spontaneous neoplastic transformation 
of cells in culture [310–316].
Selection and evolution of cells in vitro and in 
vivo is universe phenomenon. Nielsen and Briand 
[317] demonstrated chromosome abnormalities 
and karyotypic evolution in a nontumorigenic 
(tested in nude mice) and noninvasive (tested 
in vitro), spontaneously immortalized cell line 
HMT-3522, derived from a fibrocystic breast le-
sion. During 205 passages, gain and loss of mark-
ers, loss of normal chromosomes, and duplica-
tion of the chromosome complement could be 
demonstrated. The variability increased during 
in vitro growth. This variability led to cells with 
different growth capacities from which sidelines 
might be selected and become stem lines. Selec-
tion in both directions (non-tumorigenic cells to 
tumorigenic and vice versa) was also described 
[154]. This work is of special interest and all ob-
servations documented by authors are presented 
here. The karyotypic changes were associated 
with the spontaneous acquisition of tumorigenic-
ity in an immortalized human bronchial epithe-
lial cell line NL20, which had been established 
by transfection of human bronchial epithelial 
cells with the SV40 T-antigen. When cells from 
passage 184 were inoculated into nude mice, a 
transplantable tumor was obtained. Subsequent 
passages of the NL20 cells in vitro did not yield 
further tumors by passage 205. Furthermore, the 
original tumorigenic NL20T cells lost the neo-
plastic phenotype after 25 passages in vitro and 
reverted to the nontumorigenic karyotype ob-
served at passage 189. In contrast to the loss 
of the tumorigenic phenotype and karyotype, 
which occurred with in vitro passaging of the 
original tumor, when the NL20T cells were pas-
saged in other nude mice, they continued to give 
rise to tumors; cells from the secondary tumors 
(NL20T-A cells) maintained a stable karyotype 
and remained tumorigenic even after 64 passages 
in vitro. A mixture of 10 % tumorigenic NL20T-
A and 90 % nontumorigenic NL20 cells formed 
tumors in nude mice when cultured in vitro on 
fibronectin, but not on plastic; cytogenetic analy-
sis demonstrated that the tumors and cell cultures 
were composed of tumorigenic NL20T-A cells, 
whereas cells cultured on plastic were identical to 
the nontumorigenic NL20 cells. Thus, neoplastic 
transformation in original cell line arose from in 
vivo selection of a small mutant clone, which had 
arisen in culture and was subsequently selected 
in vivo but was lost in in vitro culture [154]. The 
degree of karyotype heterogeneity determines 
selection rate and correlates with tumor latent 
period [318]. The karyotypes of tumors formed 
by spontaneously transformed Chinese hamster 
cells of high tumorigenic potential after a short 
latent period were similar to each other and to 
the injected cells. The karyotypes of tumors from 
cells of low tumorigenic potential and long latent 
periods were diverse, however. No chromosome 
aberration was common to every tumor. These 
results suggested that preneoplastic cells whose 
phenotypes were not directly capable of tumor 
formation could progress in vivo and that karyo-
type instability played an important role in pro-
viding cell variants for tumor progression [318].
NIH3T3 cells were fully transformed (showed 
both anchorage independent growth in soft agar 
and tumor formation in mice) by a number of 
transforming agents depicted in Table 5. Actu-
ally, as Rubin emphasized «the effectiveness of 
the NIH3T3 cell line as a target for demonstrat-
ing the transforming capacity of oncogenes de-
pends on its partially transformed state, which 
needs only a nudge from an added oncogene to 
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progress to more advanced transformation» [315, 
319]. Unfortunately, only several works traced 
karyotype changes accompanied by oncogene 
transformation. For example, karyotypic analysis 
of parent NIH3T3 cells and NIH3T3 contain-
ing an activated N-RAS oncogene showed that, 
although the modal chromosome number was 
comparable for both cell types, number of un-
stable chromosomes and forms of abnormalities 
were different [320]. Another work demonstrated 
that parental NIH3T3 cells contained 71 chro-
mosomes (hypotetraploid), whereas EJ-NIH3T3 
(NIH3T3 cell line carrying the transfected human 
activated H-RAS sequence of EJ human blad-
der carcinoma cells) contained 60 chromosomes 
(triploid) [321]. Moreover, when the latter cells 
were treated with mutagenes (ethyl methane-
sulfonate and 8-azaguanine) and mutant clones 
were selected, they were resistant to retransfor-
mation by Kirsten sarcoma virus, DNA from EJ-
NIH 3T3 cells, H-RAS, v-SRC, v-MOS, simian 
virus 40 large T-antigen, or polyomavirus middle 
T antigen [321]. Karyotype analysis showed that 
resistant clones had hyperpentaploid karyotypes 
(103 ± 9.7 chromosomes) [321]. Transfection 
of vector containing the mitochondrial D-loop 
gene from colorectal cancer cell line SW480 
into NIH3T3 cells resulted in that NIH3T3 cells 
had significantly greater percentage of multi-
ploid and aberrant chromosomes than control 
NIH3T3, and this correlated with ability to form 
colonies in soft agar [322]. Also, other group of 
investigations suggests that for stable transforma-
tion profound changes in genome must occur 
[232, 238, 246, 323]. 
MCF10A cell line is spontaneously immortal-
ized human mammary epithelial cells with near-
diploid karyotype harboring a number of chro-
mosome abnormalities. Besides being frequently 
used in in vitro transformation assays (Table 4), 
MCF10A cell line was used for comprehensive 
analysis of the MCF10A series of cell lines rep-
resenting progression towards obvious malignancy 
[165, 324]. The MCF10A progression model con-
sists of three directly derived cell lines: the spon-
taneously immortalized MCF10A cells (do not 
show any characteristics of invasiveness or tumor 
formation), MCF10AT1 cells (MCF10A cells 
transformed by H-RAS), and MCF10CA1a cells 
(obtained from tumor in immunodeficient mice 
after xenograft transplantation of MCF10AT1 
cells) [165, 324]. 47 chromosomes were found 
in MCF10A (gained additional chromosome 8) 
and the MCF10AT1 cell lines (additional chro-
mosome 8 was deleted, but chromosome 9 was 
gained), whereas the malignant MCF10CA1a cell 
line had 50 chromosomes [165]. Four marker 
chromosomes were identified in MCF10A and 
MCF10AT1 and nine in the malignant MCF-
10CA1a cell line [165]. Spectral karyotyping anal-
ysis showed that the premalignant MCF10AT1 
gained additional translocations to the MCF10A, 
whereas the malignant MCF10CA1a had more 
translocations extra to both MCF10A and MC-
F10AT1 [165]. Array comparative genome hy-
bridization (aCGH) showed that MCF10A had 
a number of gains and losses of different chro-
mosome regions and progression towards full ma-
lignancy was accompanied by much more severe 
genomic aberrations. Importantly, regions of ge-
nomic loss/gain overlapped only partially among 
these three cell lines [165]. Another investigation 
exploiting the same model (MCF10A series of cell 
lines) confirmed the stepwise genome changes ac-
companying progression to full malignancy [324]. 
Moreover, combining SNP array with Gene Array 
authors showed correlation between DNA copy 
number gains and increased expression levels for 
genes located in these regions [324].
Analysis of tumorigenic potential of established 
seven VERO cell line strains (African green mon-
key kidney cells, the normal chromosome number 
is 60), of which 1 strain was hypotetraploid and the 
rest strains were hypodiploid, and 3 strains of HeLa 
cell line (all strains were hyperdiploid) showed that 
the cell strains were comparatively stable in terms 
of their heritable characters [325]. There were only 
little significant changes between passages but the 
tumorigenicity of strains was different among dif-
ferent karyotypic cells (from 7 VERO strains 2 ap-
peared tumorigenic: 73 ± 3, and 68 ± 3 or 65 ± 4, 
hyperdiploids and 5 were nontumorigenic: 54 ± 2,
55 ± 2, 54 ± 2, 54 ± 2, 54 ± 2, all hypodiploids), 
all HeLa strains were hyperdiploid and tumori-
genic [325]. The chromosome number variation 
of strains had positive relationships with their car-
cinogenesis and the chromosome number varia-
tion of cell line could be significantly changed 
when it developed to tumor in nude mice [325]. 
These observations were confirmed in experiments 
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with other cell cultures. Meningioma cells with 
multiple chromosomal abnormalities grew rapidly 
in vitro and induced tumors in 49 of 50 animals, 
whereas with simple karyotypes (less or 1 chromo-
somal abnormality) grew slowly in vitro and gave 
small, nongrowing tumors in mice [326]. Also, the 
average number of chromosomes in 293N cells (a 
subline of just obtained 293 cells in 1977 year de-
rived from a tumor developed in a nude mouse) 
was significantly lower than for the parental line [78].
Thus, progression of immortalized or pre-neo-
plastic cells towards obvious malignancy is always 
accompanied by karyotype changes. The degree and 
diversity of karyotype changes determine tumori-
genic potential of cell culture and latency period 
of tumor formation necessary for creation and/or 
selection of the most competitive malignant cells.
Gene copy number, mRNA and protein lev-
els relationships in tumor cells. Actually, primary 
tumor cells and cancer cell lines are always polip-
loid/aneuploid, and have karyotypes ranging from 
40 to 60 but occasionally exceeding 70 or more 
chromosomes [327]. Moreover, numerical large-
scale and focal chromosome aberrations (losses/
gains/deletions/ translocations) were found in all 
samples of each type and subtype of tumors ana-
lyzed up to now (Table 6). Roschke et al. [328] 
using spectral karyotyping provided a description 
of the chromosomal complement of the NCI-60 
cell line panel developed by the National Cancer 
Institute (NCI) for in vitro anticancer drug screen-
ing and reflecting diverse cell lineages (lung, renal, 
colorectal, ovarian, breast, prostate, central nervous 
system, melanoma, and hematological malignan-
cies). 23 cell lines were identified as near-diploid (a 
chromosome modal number between 35 and 57), 
22 as near-triploid (the chromosome modal num-
ber between 58 and 80), 13 as near-tetraploid (a 
chromosome modal number between 81 and 103), 
and 1 as near-pentaploid (chromosome modal 
number between 104 and 126) on the basis of the 
International System for Chromosome Nomen-
clature. The range of numerical changes (clonal 
chromosome gains and losses) ranged from 1 to 28. 
Number of structurally rearranged chromosomes 
(contained translocations, deletions, duplications, 
insertions, inversions, or homogeneously staining 
regions) ranged from 1 to 45 (38 cell lines had 10 
and more structurally rearranged chromosomes). In 
addition, in 24 of the 59 cell lines ploidy heteroge-
neity was found (i.e., if the majority of cells had a 
near-triploid karyotype there might be an additional 
small populations of cells with a near-pentaploid 
or near-hexaploid count, or, in few cases, with a 
near-diploid count). Chromosome numerical and 
structural heterogeneity between cells in the same 
cell line was also documented [328]. 
Later, this NCI-60 cell line panel was used 
to elucidate correlation between gene copy num-
ber and mRNA levels for the same gene. The 
data showed a generally positive correlation be-
tween a given gene’s copy number and its ex-
pression at the mRNA level supporting the gen-
eralization that DNA copy number is one factor 
(among others) that can influence gene expres-
sion [329]. In another work authors performed a 
global analysis of both mRNA and protein levels 
based on sequence-based transcriptome analysis 
(RNA-seq) and SILAC-based mass spectrom-
etry analysis [330]. The study was performed 
in three functionally different human cell lines 
(the glioblastoma cell line U251MG, the epi-
dermoid carcinoma cell line A431 and the osteo-
sarcoma cell line U2OS). The changes of mRNA 
and protein levels in the cell lines using SILAC 
and RNA ratios showed high correlations, even 
though the genome-wide dynamic range was sub-
stantially higher for the proteins as compared with 
the transcripts [330]. Also, there was a moderate 
but significant correlation between global mRNA 
(RNA-seq) and protein levels (SILAC) of 1710 
genes affected by amplification or deletion (SNP 
and CGH arrays) in seven human metastatic mela-
noma cell lines [331]. Whether does it mean that 
the end point of gene expression, the level of pro-
tein, is affected proportionally to copy number of 
gene in tumor cells? Measurement of expression 
levels of 6735 proteins was directly compared to 
the gene copy number in MCF7 breast cancer cell 
line [332]. Authors found that in the majority of 
cases, there was no direct correspondence between 
the gene copy number change and the correspond-
ing protein change. Nevertheless, proteins encoded 
by amplified oncogenes were often overexpressed, 
while adjacent amplified genes, which presumably 
did not promote growth and survival, were attenua-
ted [332]. Furthermore, authors revealed that the 
proteins of such complexes as the proteasome, ribo-
some, spliceosome, and NADH dehydrogenase al-
ways maintained equal protein ratios, despite varia-
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tion in the gene copy number of their subunits. This 
was strictly true for the core complexes components, 
but to a lesser degree for peripheral proteins, which 
could also be involved in other processes [332]. In-
terestingly, levels of protein expression in aneuploid 
yeast strains largely scale with chromosome copy 
numbers, following the same trend as that observed 
for the transcriptome [333]. Thus, eventually to be 
definitely concluded, relationships between gene 
copy number, mRNA level and protein level of indi-
vidual genes across the whole cancer genome should 
be analyzed. It would give the comprehensive under-
standing to which degree regulation of gene expres-
sion on different levels operates in tumor cells and 
which groups of genes are predominantly imposed 
on such regulation.  
Inter- and intratumor heterogeneity. It is sup-
posed that common (clonal) chromosome changes 
are the «drivers» of neoplastic transformation 
whereas rare chromosome changes (non-clonal) 
are likely the «passengers» in this process, which 
may be either nonfunctional or functional but con-
stitute secondary events [3, 374, 375]. Nevertheless, 
non-clonal aberrations reflect the significant tumor 
feature: genome/chromosome instability and, as a 
consequence, inter- and intratumor genome het-
erogeneity [376]. Importantly, the main determi-
nant of the ability of a population to evolve is the 
extent of heritable variation within the population 
[377]. Numerous studies have proved that intra-tu-
mor genetic heterogeneity/clonal diversity is a key 
force driving transformation and tumor evolution 
(Stepanenko and Kavsan, in preparation).
Nobusawa et al. [374] have analysed by 
aCGH separate tumor areas of 14 primary glio-
blastomas (total, 41 tumor areas). They revealed 
Table 6
Tumors and cell lines with multiple chromosomal abnormalities
Indications. aCGH – array comparative genome hybridization; SNP array – single nucleotide polymorphism 
array; Sequencing – massively parallel paired-end sequencing; MLDPA – multiple ligation-dependent probe 
amplification. 
Cancer type Method
Number 
of samples Ref.
Acute myeloid leukemia
Bladder cancer
Bladder carcinomas
Breast cancer
Cervical carcinomas
Colorectal carcinomas and adenomas
Endometrial carcinomas and carcinosarcomas
Ewing’s cancer
Gastric cancer 
Germ cell cancer
Glioma
Head and neck squamous cell carcinomas
Lung cancer
Myelodysplastic syndromes and related 
myeloid malignancies
Oral carcinomas
Oropharynx and hypopharynx squamous cell 
carcinomas
Ovarian epithelial tumors
Pancreatic carcinomas
Prostate tumours
Thyroid carcinomas and  adenomas
29 different tissues
26 different tissues
aCGH
aCGH
aCGH
aCGH, SNP array, sequencing, 
aCGH, SNP array
aCGH, SNP array
aCGH and karyotyping
aCGH, spectral karyotyping
aCGH
aCGH
aCGH, SNP array, karyotyping
aCGH
Sequencing, SNP array, karyotyping
SNP array, karyotyping
aCGH
aCGH
aCGH
aCGH, sequencing
Sequencing
aCGH
aCGH
SNP array
17
22 
109 
1143
40
129
82
7 
31 
24
248
43
80
430
60
20
47
37
7
28
598 
3131 
[334 ]
[335]
[336, 337]
[338–342]
[343, 344]
[345–348]
[349]
[350]
[351]
[352]
[353–359]
[360, 361]
[362, 363]
[364]
[365]
[366]
[367]
[368, 369]
[370]
[371]
[372]
[373]
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that chromosomal imbalances significantly dif-
fered among glioblastomas. In addition, there 
were numerous tumor area-specific genomic im-
balances. Analysis of disseminated single cells in 
minimal residual disease has shown that there is a 
high level of genomic heterogeneity within indi-
vidual lesions as well as between primary tumors 
and metastatic cells [376]. Giving comments on 
reports of breast cancer genomes analyses with 
high-throughput genomics thechnics [339, 342], 
Swanton et al. [378] concluded that results from 
these studies had revealed «perplexing breast can-
cer genome complexity with very few aberrations 
occurring in common between breast cancers. In 
addition, such complexity is compounded by evi-
dence of profound genomic heterogeneity within 
individual breast tumors (intratumoral hetero-
geneity), where multiple tumor subpopulations 
have been identified, each with distinct genomic 
profiles heterogeneity occurring within individual 
breast cancers». Moreover, recurrent tumors al-
ways show appearance of new chromosome im-
balances and gene mutations distinct from those, 
which were observed in most cells of a primary 
tumor but could be harbored by a small group of 
cells within a primary tumor or acquired de novo 
[371, 377, 380–389].
Intratumor genomic heterogeneity is created 
and fostered by chromosome instability (CIN. Al-
though defects in chromosome cohesion, kinet-
ochore-microtubule misattachments, assembly
of multipolar mitotic spindles [182, 390–396], 
translocations containing breakpoints within fra-
gile sites [397], satellite repeats in heterochro-
matin [398], cell-in-cell formation by entosis (as 
a result, cytokinesis frequently fails, generating 
binucleate cells that produce aneuploid cell lin-
eages) [399], random fragmentation of the entire 
chromosome (chromothripsis) in which chromo-
somes are broken into many pieces and then 
randomly stitched back together [400, 401] can 
contribute to CIN, in cancer cells mechanism 
of centrosome amplification and clustering is 
proposed to be the major contributor to CIN. 
Importantly, there is compelling evidence that 
diverse oncogenes or carcinogenes induce cen-
trosome deregulation and CIN (Stepanenko and 
Kavsan, in preparation). 
Inter- and intratumor heterogeneity of gene 
mutations was also revealed by sequencing of all 
protein coding genes in several solid tumors, in-
cluding glioblastomas, colorectal, pancreatic and 
breast cancers. It was found that individual solid 
organ tumors harbor approximately 40–80 clonal 
mutations per tumor in the coding regions of dif-
ferent genes, and although a few of these genes are 
mutated in a high proportion of tumors, the preva-
lence at which the majority are mutated among dif-
ferent tumors of the same cancer type is low [376, 
377, 402]. 2576 somatic mutations were identified 
across 1800 megabases of DNA representing 1507 
coding genes from 441 tumors comprising breast, 
lung, ovarian and prostate cancer types and sub-
types [403]. Authors found that mutation rates and 
the sets of mutated genes varied substantially across 
tumor types and subtypes. Results of sequencing 
COLO-829 cancer cell line derived, before treat-
ment, from a metastasis of a malignant melanoma 
demonstrated a total of 292 somatic base substitu-
tions in protein-coding sequences [404]. As Fox et 
al. stated «each tumor displays a unique and diverse 
profile of mutated genes, but no new prevalently 
mutated genes are identified... Within an individual 
neoplasm, a few mutations are present throughout 
the population, a greater number are present in mi-
nority subclones, and the majority is found in only 
one or a few cells» [376]. Actually, if to calculate all 
abnormalities of noncoding genome regions, there 
are usually between 1000 and 10000 somatic sub-
stitutions in the genomes of most adult tumors, in-
cluding breast, ovary, colorectal, pancreas cancers, 
and glioma [3]. All these data imply that tumors are 
really «oncogene addicted», but it has not revealed 
a possible «Achilles’ heel» within the cancer cell 
that can be exploited therapeutically [3, 405], be-
cause «instead of long-anticipated common muta-
tions, a large number of stochastic gene mutations 
were detected for each individual with the same 
cancer type» [406]. 
Chromosome instability and drug resistance. 
Cancer cells rapidly acquire resistance against 
numerous cytotoxic drugs or are even intrinsically 
resistant [379]. The chromosomes of cancer cells 
are extremely unstable compared to those of normal 
cells: 1 in 100 highly aneuploid human cancer cells 
loses or gains or rearranges a chromosome per 
cell generation [407]. Genetic variation within a 
cancer cell population reflects dynamics of clonal 
evolution and, importantly, serves as a reservoir 
of genetic diversity from which therapy-resistant 
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clones may arise [376]. In vitro studies have con-
firmed that CIN cells acquire multidrug resistance 
at an accelerated rate compared with diploid cells 
resulting from the selection pressure influenced by 
drug exposure. Moreover, mouse CIN cells be-
came multidrug resistant even after deletion of all 
known multidrug resistance genes [319, 379]. To 
identify distinct therapeutic approaches to specifi-
cally limit the growth of CIN tumors, Lee et al. 
[408] focused on a panel of colorectal cancer cell 
lines, previously classified as either chromosom-
ally unstable, CIN (+), or diploid/near-diploid, 
CIN (–), and treated them individually with a 
library of kinase inhibitors targeting components 
of signal transduction, cell cycle, and transmem-
brane receptor signaling pathways. CIN (+) cell 
lines displayed significant intrinsic multidrug re-
sistance compared with CIN (–) cancer cell lines, 
and this seemed to be independent of somatic mu-
tation status and proliferation rate [408]. 
According to Duesberg et al., karyotype plays 
the central role in drug resistance [379]. «When 
cancer cells acquire resistance against drugs, they 
acquire new karyotypic alterations and/or they 
lose old ones». Indeed, gene expression profiles 
of drug resistant cells differ from those of parental 
drug sensitive cells in the over- or underexpression 
of hundreds to thousands genes [379]. Comparison 
of the structures of the puromycin resistance-
specific chromosomal alterations in four different 
human colon cancer lines indicates, that most 
but not all of resistance-specific chromosomal 
alterations were unique for each cancer cell [379]. 
Drug resistance correlates with chromosomal
alterations [319, 407]. It is generated de novo in 
cancer cells by chromosome re-assortments [379]. 
The resulting level of resistance is proportional to 
the numbers of resistance-specific chromosomal 
alterations or «tumor heterogeneity» [379]. In the 
presence of cytotoxic drugs resistance-specific 
alterations are selected from the resultining vari-
ants by classical Darwinian mechanisms [379]. 
Ñhromosome instability, intertumoral and intra-
tumoral heterogeneity present a challenge to per-
sonalized therapeutic approaches [378].
Conclusion. The intense searching for the ab-
normal genes influencing the development of hu-
man cancer revealed about 200000 somatic mu-
tations in cancer genomes (COSMIC database)
since the first somatic mutation that was found in 
H-RAS the quarter of a century ago [198]. Hun-
dreds of genes are being considered and dozens 
genes/proteins have been used already as poten-
tial drug targets in clinical trials. However, at 
present benefits from oncogene directed therapy 
are still moderate. Large-scale tumor genome se-
quencing have failed to reveal «universal» can-
cer genes and, instead, «large numbers of diverse 
mutations have been identified dominating the 
cancer genome landscape» [406]. «A future of 
multiple targeted therapies and patient stratifica-
tion, based on a mutational signature of defined 
key genes for each cancer type, seems less hope-
ful than initially anticipated» [376]. 
Now it is clear that «cancer progression is a 
stochastic process both at the genome and gene 
level, and is not a stepwise process defined by 
sequential genetic aberrations. Stochastic pro-
cess frequently occurs prior to the key stages of 
immortalization, transformation and metasta-
sis and results in inability to detect type- and 
stage-specific recurrent aberrations in solid tu-
mors» [406]. Numerous somatic rearrangements, 
including whole chromosome and copy number 
gains and losses, chromosome translocations, 
and gene mutations participate in establishing 
the malignant cell phenotype. «Multiple rounds 
of proliferation, often counter-balanced by cell 
death, are required to produce macroscopic tu-
mors, and genomic instability, observed in most 
cancers, is expected to constantly produce new 
mutations, which serve as raw material on which 
tumor evolution can work» [409]. The selection 
may weed out cells that have acquired deleteri-
ous mutations or it may foster cells carrying al-
terations that confer the capability to proliferate 
and survive more effectively than their neighbors 
[198]. A single cell can acquire a set of suffi-
ciently advantageous mutations that allows it to 
proliferate autonomously, invade tissues and me-
tastasize [198]. 
CIN is the most common genetic abnormality 
of cancer cells and tumorigenic cell lines. The fre-
quent losses and gains of whole chromosomes dur-
ing cell divisions in CIN cancer cells trigger rapid 
alterations in gene dosage [379]. In vitro studies 
have confirmed that CIN cells acquire multi-drug 
resistance at an accelerated rate compared with 
diploid cells [379]. Furthermore, although most 
cancers are of monoclonal origin, the expansion of 
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the population size, which occurs after malignant 
transformation, coupled with the constant acquisi-
tion of mutations promotes the diversion into sub-
clones and a dramatic increase in genetic tumor 
heterogeneity [377]. High genetic heterogeneity 
of tumors means high probability of pre-existent 
clones that are resistant to therapeutic intervention 
and can be selected by therapy resulting in therapy 
failure [409]. Severe genome rearrangements and 
intratumoral heterogeneity challenge oncogene di-
rected therapy, while chromosome instability and 
karyotype evolution make each tumor «a moving 
rather than frozen» target. 
Thus, a main driver of evolutionary adaptation 
during drug treatment is the genetic heterogeneity, 
which is fostered by CIN. New tools are necessary 
to study heterogeneity and to analyze changes in 
heterogeneity and clonal composition during drug 
treatment [410–412]. This would allow new in-
sights into these processes and provide the basis 
to improve therapeutic outcomes based on tumor 
evolution and the specific targeting of distinct ge-
nomic instability mechanisms [377, 413].
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ÈÌÌÎÐÒÀËÈÇÀÖÈß 
È ÇËÎÊÀ×ÅÑÒÂÅÍÍÀß ÒÐÀÍÑÔÎÐÌÀÖÈß 
ÝÓÊÀÐÈÎÒÈ×ÅÑÊÈÕ ÊËÅÒÎÊ
×òîáû ñòàòü ïîëíîñòüþ òðàíñôîðìèðîâàííîé îïó-
õîëåâîé êëåòêîé, íîðìàëüíàÿ êëåòêà äîëæíà ïðå-
îäîëåòü ðÿä âíóòðåííèõ êëåòî÷íûõ áàðüåðîâ è ïðè-
îáðåñòè áîëüøîå ÷èñëî õðîìîñîìíûõ èçìåíåíèé.
Ïåðâûì è íåîáõîäèìûì øàãîì â çëîêà÷åñòâåííîé 
òðàíñôîðìàöèè ÿâëÿåòñÿ ïðåîäîëåíèå ñòàðåíèÿ, èëè 
èììîðòàëèçàöèÿ êëåòêè. Èììîðòàëèçèðîâàííûå 
êëåòêè ìîãóò áåñêîíå÷íî äîëãî ïðîëèôåðèðîâàòü â 
ïðèñóòñòâèè ðîñòîâûõ ôàêòîðîâ è ïèòàòåëüíûõ âå-
ùåñòâ. Èììîðòàëèçèðîâàííûå êëåòêè íèêîãäà íå
èìåþò íîðìàëüíîãî äèïëîèäíîãî êàðèîòèïà, xoòÿ 
âî âðåìÿ ðîñòà ïîäâåðãàþòñÿ êîíòàêòíîìó èíãèáè-
ðîâàíèþ, íå ôîðìèðóþò êîëîíèé â ìÿãêîì àãàðå (ò.å. 
çàâèñèìûé îò ïîäëîæêè ðîñò) è íå ôîðìèðóþò îïóõîëåé 
ïðè ââåäåíèè èììóíîäåôèöèòíûì ìûøàì. Âñå ýòè 
ñâîéñòâà ìîãóò áûòü ïðèîáðåòåíû ñ äîïîëíèòåëüíû-
ìè õðîìîñîìíûìè èçìåíåíèÿìè. Ìíîæåñòâåííûå ãå-
íåòè÷åñêèå èçìåíåíèÿ, âêëþ÷àÿ ïðèîáðåòåíèå/ïîòå-
ðþ öåëûõ õðîìîñîì èëè îòäåëüíûõ ó÷àñòêîâ/ëîêó-
ñîâ, òðàíñëîêàöèþ õðîìîñîì è ãåííûå ìóòàöèè,
íåîáõîäèìû äëÿ óñòàíîâëåíèÿ òðàíñôîðìèðîâàííî-
ãî ôåíîòèïà. Ïðîöåññ êëåòî÷íîé òðàíñôîðìàöèè äî-
ñòàòî÷íî õîðîøî èçó÷åí íàêëåòî÷íûõ êóëüòóðàõ
in vitro. Áîëüøèíñòâî ýêñïåðèìåíòîâ, âûÿâèâøèõ
òðàíñôîðìèðóþùóþ ñïîñîáíîñòü ãåíîâ (îíêîãåíîâ), 
íàäýêñïðåññèðîàííûõ è/èëè ìóòèðîâàííûõ â îïóõî-
ëÿõ, áûëî âûïîëíåíî ñ èñïîëüçîâàíèåì òàêèõ êëåòî÷-
íûõ êóëüòóð, êàê ìûøèíûå ýìáðèîíàëüíûå ôèáðîáëà-
ñòû (MEFs), ìûøèíàÿ êëåòî÷íàÿ ëèíèÿ ôèáðîáëàñòîâ 
NIH3T3, êëåòî÷íàÿ ëèíèÿ ÷åëîâå÷åñêîé ýìáðèî-
íàëüíîé ïî÷êè 293 (293 êëåòêè) è ýïèòåëèàëüíûå 
êëåòî÷íûå ëèíèè ìîëî÷íîé æåëåçû ÷åëîâåêà (ãëàâ-
íûì îáðàçîì, HMECs è MCF10A), êîòîðûå ïðåäñòàâ-
ëÿþò ñîáîé èììîðòàëèçèðîâàííûå êëåòêè (êðî-
ìå ïåðâè÷íûõ ìûøèíûõ ôèáðîáëàñòîâ) ñ èçìåíåí-
íûìè ãåíîìàìè (ïîëè-/àíåóïëîèäû ñî çíà÷èòåëü-
íûìè õðîìîñîìíûìè ïåðåñòðîéêàìè) è ñêëîííûå ê
ïîëíîé çëîêà÷åñòâåííîé òðàíñôîðìàöèè ïðè êóëü-
òèâèðîâàíèÿ. Íåäàâíî îáíîâëåííûé ñïèñîê îíêî-
ãåíîâ âêëþ÷àåò áîëåå 467 ãåíîâ, êîòîðûå, êàê ïî-
ëàãàþò, âîâëå÷åíû â ðàçâèòèå îïóõîëè, êîãäà ñî-
îòâåòñòâåííûì îáðàçîì èçìåíåíû (òî÷êîâûå ìóòà-
öèè, äåëåöèè, òðàíñëîêàöèè èëè àìïëèôèêàöèè). 
Îäíàêî èññëåäîâàíèÿ íà ìûøàõ ñâèäåòåëüñòâóþò, 
÷òî áîëåå 3000 ãåíîâ ìîãóò âíîñèòü âêëàä â 
ðàçâèòèå îïóõîëè. Öåëüþ íàñòîÿùåãî îáçîðà ÿâ-
ëÿåòñÿ ïîíÿòü ìåõàíèçìû êëåòî÷íîé èììîðòàëè-
çàöèè ðàçëè÷íûìè «èììîðòàëèçóþùèìè àãåíòàìè»,
îíêîãåí-èíäóöèðóåìîé êëåòî÷íîé òðàíñôîðìàöèè 
èììîðòàëèçèðîâàííûõ êëåòîê è óìåðåííûé îòâåò íà 
òåðàïèþ èç-çà «ñêëîííîñòè» îïóõîëè ê ïðèîáðåòå-
íèþ ìíîãî÷èñëåííûõ ãåííûõ è õðîìîñîìíûõ èçìå-
íåíèé, âíóòðè- è ìåæîïóõîëåâîé ãåòåðîãåííîñòè. 
Î.À. Ñòåïàíåíêî, Â.Ì. Êàâñàí
²ÌÎÐÒÀË²ÇÀÖ²ß 
ÒÀ ÇËÎßÊ²ÑÍÀ ÒÐÀÍÑÔÎÐÌÀÖ²ß 
ÅÓÊÀÐ²ÎÒÈ×ÍÈÕ ÊË²ÒÈÍ
Ùîá ñòàòè ïîâí³ñòþ òðàíñôîðìîâàíîþ ïóõ-
ëèííîþ êë³òèíîþ, íîðìàëüíà êë³òèíà ïîâèííà 
ïîäîëàòè íèçêó âíóòð³øí³õ êë³òèííèõ áàð’ºð³â ³ 
ïðèäáàòè âåëèêó ê³ëüê³ñòü õðîìîñîìíèõ çì³í. Ïåð-
øèì íåîáõ³äíèì êðîêîì ó çëîÿê³ñí³é òðàíñôîðìàö³¿ 
º ïîäîëàííÿ ñòàð³ííÿ, àáî ³ìîðòàë³çàö³ÿ êë³òèíè. 
²ìîðòàë³çîâàí³ êë³òèíè ìîæóòü íåñê³í÷åííî äîâãî 
ïðîë³ôåðóâàòè â ïðèñóòíîñò³ ðîñòîâèõ ôàêòîð³â ³
ïîæèâíèõ ðå÷îâèí. ²ìîðòàë³çîâàí³ êë³òèíè ìàéæå 
í³êîëè íå ìàþòü íîðìàëüíîãî äèïëî¿äíîãî êàð³î-
òèïó, òèì íå ìåíø âîíè ï³ä ÷àñ ðîñòó ï³ääàþòüñÿ 
êîíòàêòíîìó ³íã³áóâàííþ, íå ôîðìóþòü êîëîí³é â 
ì’ÿêîìó àãàð³ (òîáòî çàëåæíå â³ä ï³äêëàäêè çðîñ-
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òàííÿ) ³ íå ôîðìóþòü ïóõëèí ïðè ââåäåíí³ ³ìóíî-
äåô³öèòíèì ìèøàì. Âñ³ ö³ âëàñòèâîñò³ ñòàá³ëüíî
ìîæóòü áóòè ïðèäáàí³ ç äîäàòêîâèìè õðîìîñîì-
íèìè çì³íàìè. Ìíîæèíí³ ãåíåòè÷í³ çì³íè, âêëþ÷à-
þ÷è íàáóòòÿ àáî âòðàòó ö³ëèõ õðîìîñîì àáî îêðåìèõ 
ä³ëÿíîê/ëîêóñ³â, òðàíñëîêàö³ÿ õðîìîñîì ³ ãåíí³ ìó-
òàö³¿, º íåîáõ³äíèìè äëÿ âñòàíîâëåííÿ òðàíñôîðìî-
âàíîãî ôåíîòèïó. Ïðîöåñ êë³òèííî¿ òðàíñôîðìàö³¿ 
äîñèòü äîáðå âèâ÷åíèé íà êë³òèííèõ êóëüòóðàõ 
in vitro. Á³ëüø³ñòü åêñïåðèìåíò³â ç âèÿâëåííÿ 
òðàíñôîðìóþ÷î¿ çäàòíîñò³ ãåí³â (îíêîãåí³â), íàä-
åêñïðåñîâàíèõ òà/àáî ìóòîâàíèõ â ïóõëèíàõ, áóëî 
âèêîíàíî ç âèêîðèñòàííÿì òàêèõ êë³òèííèõ êóëü-
òóð, ÿê ìèøà÷³ åìáð³îíàëüí³ ô³áðîáëàñòè (MEFs), 
êë³òèííà ë³í³ÿ ìèøà÷èx ô³áðîáëàñò³â NIH3T3, 
êë³òèííà ë³í³ÿ ëþäñüêî¿ åìáð³îíàëüíî¿ íèðêè 293 
(293 êë³òèíè) ³ åï³òåë³àëüí³ êë³òèíí³ ë³í³¿ ìî-
ëî÷íî¿ çàëîçè ëþäèíè (ãîëîâíèì ÷èíîì, HMECs 
³ MCF10A), ÿê³ ïðåäñòàâëÿþòü ñîáîþ ³ìîðòàë³-
çîâàí³ êë³òèíè (êð³ì ïåðâèííèõ ìèøà÷èõ ô³áðî-
áëàñò³â) ç³ çì³ííèìè êàð³îòèïàìè (ïîë³-/àíåó-
ïëî¿äè ç³ çíà÷íèìè õðîìîñîìíèìè ïåðåáóäîâàìè) 
³ ñõèëüí³ äî ïîâíî¿ çëîÿê³ñíî¿ òðàíñôîðìàö³¿ ïðè 
êóëüòèâóâàíí³. Íåùîäàâíî îíîâëåíèé ñïèñîê îíêî-
ãåí³â âêëþ÷àº ïîíàä 467 ãåí³â, ùî çàëó÷åí³, ÿê 
ââàæàþòü, äî ðîçâèòêó ïóõëèíè, êîëè â³äïîâ³äíèì 
÷èíîì çì³íåí³ (òî÷êîâ³ ìóòàö³¿, äåëåö³¿, òðàíñëîêàö³¿ 
àáî àìïë³ô³êàö³¿). Îäíàê äîñë³äæåííÿ íà ìèøàõ 
ñâ³ä÷àòü ïðîòå, ùî ïîíàä 3000 ãåí³â ìîæóòü ðî-
áèòè âíåñîê ó ðîçâèòîê ïóõëèíè. Ìåòà äàíîãî 
îãëÿäó çðîçóì³òè ìåõàí³çìè êë³òèííî¿ ³ìîðòàë³çàö³¿ 
ð³çíèìè «³ìîðòàë³çóþ÷èìè àãåíòàìè», îíêîãåí-
³íäóêîâàíî¿ êë³òèííî¿ òðàíñôîðìàö³¿ ³ìîðòàë³çîâà-
íèõ êë³òèí ³ ïîì³ðíó â³äïîâ³äü íà òåðàï³þ ÷åðåç 
«ñõèëüí³ñòü» ïóõëèíè äî ïðèäáàííÿ ÷èñëåííèõ 
ãåííèõ òà õðîìîñîìíèõ çì³í òà ãåòåðîãåíí³ñòþ 
óñåðåäèí³ ³ ì³æ ïóõëèíàìè.
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